

# BMJ Open

## PREVALENCE OF CLINICALLY SIGNIFICANT DECISIONAL CONFLICT: A POOLED ANALYSIS OF FIVE STUDIES ON DECISION MAKING IN PRIMARY CARE

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-011490
Article Type:	Research
Date Submitted by the Author:	19-Feb-2016
Complete List of Authors:	Thompson-Leduc, Philippe; CHU de Quebec and Universite Laval, Population Health and Practice-Changing Research Group Turcotte, Stéphane; Chu de Québec, Population Health and Practice-Changing Research Group Labrecque, Michel; Universite Laval, Department of Family Medicine and Emergency Medicine; CHU de Québec, Population Health and Practice-Changing Research Group Legare, France; Laval University, Department of Family Medicine and Emergency Medicine; CHU de Québec, Population Health and Practice-Changing Research Group
<b>Primary Subject Heading</b>:	General practice / Family practice
Secondary Subject Heading:	Epidemiology, Patient-centred medicine
Keywords:	Decisional conflict, shared decision making, PRIMARY CARE

SCHOLARONE™  
Manuscripts

only

**TITLE:**

PREVALENCE OF CLINICALLY SIGNIFICANT DECISIONAL CONFLICT: A  
POOLED ANALYSIS OF FIVE STUDIES ON DECISION MAKING IN PRIMARY  
CARE

**AUTHORS:**

Philippe THOMPSON-LEDUC<sup>1</sup>, Stéphane TURCOTTE<sup>1</sup>, Michel LABRECQUE<sup>1,2</sup>,  
France LÉGARÉ<sup>1,2</sup>

1. Population Health and Practice-Changing Research Group, Centre Hospitalier

Universitaire de Québec Research Centre, Quebec City, Canada

2. Department of Family Medicine and Emergency Medicine, Faculty of Medicine, Laval

University, Quebec City, Canada

**CORRESPONDING AUTHOR:**

France Légaré, MD, PhD, CCMF, FCMF

Centre Hospitalier Universitaire de Québec Research Centre

Hôpital St-François d'Assise

10, rue Espinay, Québec

Québec, Canada

Phone : 418 525-4437

Fax: 418 525-4194

[france.legare@mfa.ulaval.ca](mailto:france.legare@mfa.ulaval.ca)

### **FUNDING STATEMENT:**

FL is Tier-2 Canada Research Chair in Implementation of Shared Decision Making in Primary Care.

### **CONTRIBUTORS STATEMENT**

Conceived and designed the analysis plan: FL, ML, PTL, ST. Analyzed the data: FL, ML, PTL, ST. Wrote the paper: FL, PTL. Critically reviewed the manuscript for important intellectual content: FL, PTL, ML, ST. Read and approved the final version: FL, PTL, ML, ST. Guarantors: FL, PTL

### **PRIOR PRESENTATION:**

This manuscript is original and is not being considered for publication elsewhere.

**WORD COUNT: 3075/4000**

### **NUMBER OF TABLES, FIGURES, APPENDICES:**

Tables: 3

Figures: 0

Appendices: 0

### **ABBREVIATIONS:**

1  
2  
3 CI: Confidence intervals  
4  
5 CSDC: Clinically Significant Decisional Conflict  
6  
7  
8 DCS: Decisional Conflict Scale  
9  
10  
11 FPTU: Family Practice Teaching Unit  
12  
13 OR: Odds ratio  
14  
15 PBRN: Practice-based Research Network  
16  
17  
18  
19

20 **KEYWORDS (3):**

21  
22 Decisional conflict, shared decision making, primary care  
23  
24  
25  
26

27 **ACKNOWLEDGEMENTS:**

28  
29 The authors wish to thank Louisa Blair for editing this manuscript.  
30  
31  
32  
33

34 **CONFLICT OF INTEREST STATEMENT:**

35  
36 The authors declare no conflict of interest.  
37  
38  
39  
40

41 **DATA SHARING STATEMENT:**

42  
43 No additional data are available.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**ABSTRACT (297/300 WORDS)**

**Objectives:** Unresolved clinically significant decisional conflict (CSDC) in patients following a consultation with a health professional is often the result of inadequate patient involvement in decision making and may result in poor outcomes. We sought to identify the prevalence of CSDC in studies on decision making in primary care contexts and to explore its risk factors.

**Setting:** We performed a secondary analysis of existing datasets from studies conducted in Primary Care Practice-Based Research Networks in Quebec and Ontario, Canada.

**Participants:** Eligible studies included a patient-reported measure on the 16-item Decisional Conflict Scale (DCS) following a decision made with a healthcare professional with no study design restriction.

**Primary and secondary outcome measures:** CSDC was defined as a score  $\geq 25/100$  on the DCS. The prevalence of CSDC was stratified by sex; and patient-level logistic regression analysis was performed to explore its potential risk factors. Datasets of studies were analyzed individually and qualitatively compared.

**Results:** Five projects conducted between 2003 and 2010 were included. They covered a range of decisions: prenatal genetic screening, antibiotics for acute respiratory infections and miscellaneous. They included a total of 1338 primary care patients (69% female;

1  
2  
3 range of age: 15 to 83). The prevalence of CSDC in patients varied across studies and  
4  
5 ranged from 10.3% (95% confidence interval: 7.2% – 13.4%) to 31.1% (95% confidence  
6  
7 interval: 26.6% – 35.6%). Across the five studies, risk factors of CSDC included being  
8  
9 male, living alone, and being 45 or older.  
10  
11

12  
13  
14  
15 **Conclusions:** Prevalence of CSDC in patients who had enrolled in studies conducted in  
16  
17 primary care contexts was substantial and appeared to vary according to the type of  
18  
19 decision as well as to patient characteristics such as sex, living arrangement and age.  
20  
21 Patients presenting risk factors of CSDC should be offered decision aids to increase their  
22  
23 involvement in decision making.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Strengths and limitations of this study

- This study included data on 1338 patients from five studies conducted in primary care contexts in two Canadian provinces, Quebec and Ontario.
- To the best of our knowledge, this is the first account of the prevalence of CSDC as reported in studies conducted exclusively in primary care and with this many unique clinical encounters. None of the earlier studies measuring CSDC in a primary care clinical context focused on a decision dealt with entirely at the primary care level.
- Our results 1) contradict a common belief that primary care only deals with mundane types of decision that involve no risk, loss, regret, or challenges to personal life values, and that primary care decisions therefore involve little personal uncertainty; 2) report a higher prevalence of CSDC in men than in women in all four datasets that included men and women; 3) show that people reporting living alone experienced a consistently higher prevalence of CSDC than people reporting living with at least one other person; and 4) reveal that older patients showed a higher prevalence of CSDC in all relevant datasets.
- The fact that measuring CSDC was not the primary objective of any of the selected studies could affect interpretation of the results.
- A meta-analysis was not possible given the heterogeneity of the data sets (type of decision, study design, available variables).

## INTRODUCTION

When facing health-related decisions and presented with multiple options, patients are subject to uncertainty about what to choose. This uncertainty is known as decisional conflict. Decisional conflict is an intra-personal psychological construct that is felt by individuals when facing decisions that involve risk, loss, regret, or challenges to personal life values.<sup>1 2</sup> In lay terms, decisional conflict reflects the level of comfort that an individual faces in making a decision. In some patients it may translate into clinically significant decisional conflict (CSDC), at which point decisional conflict is positively associated with decisional delay, departure from active treatment, decision regret, nervousness and a higher intention to sue physicians in cases of harms from treatment.<sup>3 4</sup> Thus it is essential to identify patients experiencing CSDC, as there are several modifiable deficits that lead to CSDC, including 1) inadequate knowledge of options; 2) unclear values regarding harms and benefits of options; and 3) inadequate support or resources for decision making. These may all be addressed with effective decision support.<sup>5</sup>

In primary care CSDC may be particularly relevant. Primary care is defined as the level of the healthcare system that provides individuals with: 1) a gateway into the system for all their needs and problems; 2) care focused on the individual and their context (not disease-oriented); 3) care for all but very uncommon or unusual conditions; 4) continuity of care; and 5) the coordination or integration of the care provided by other levels of the system or by other professionals.<sup>6</sup>

Primary care is also a context in which the available evidence is often equivocal, goals are often ill-defined, and decision making is subject to structural, organizational and time pressures.<sup>7-9</sup>

While lack of information, unclear values and insufficient support can make decision making



1  
2  
3 more difficult, these difficulties can be addressed successfully with effective decision support.<sup>5</sup>  
4  
5 For example, patient decision aids have proven to be effective in resolving CSDC following the  
6  
7 decision-making process.<sup>10 11</sup> Analyzing and comparing the outcomes of studies on decision  
8  
9 making among primary care patients could thus have a beneficial impact on the quality of care  
10  
11 for a large number of individuals. We sought to identify the prevalence of CSDC in studies  
12  
13 conducted in primary care contexts and to explore its risk factors.  
14  
15  
16  
17  
18  
19

## 20 METHODS

### 21 *Source of data and participants*

22  
23  
24  
25  
26  
27  
28  
29 We carried out a secondary analysis of existing datasets from studies conducted within or in  
30  
31 collaboration with the Laval University Primary Care Practice-Based Research Network (PBRN)  
32  
33 in the Province of Quebec, Canada. This network comprises twelve family practice teaching  
34  
35 units affiliated with Laval University and collaborates with other research networks nationally  
36  
37 and internationally.<sup>12</sup> We screened the Laval University PBRN for potentially eligible studies  
38  
39 and considered all patient data gathered from five eligible studies. Studies were included if 1)  
40  
41 they were set entirely in primary care (defined as the patient's point of entry into the healthcare  
42  
43 system, most often consulting a family physician<sup>13</sup>); 2) they assessed patient-reported decisional  
44  
45 conflict using the French or English version of the 16-item Decisional Conflict Scale (DCS)<sup>14</sup>;  
46  
47 and 3) DCS scores were collected from patients following a clinical encounter with a primary  
48  
49 care provider. There was no study design restriction. Studies were excluded if data had been  
50  
51 gathered in a specialized clinic, if participants were recruited from the public (through newspaper  
52  
53  
54  
55  
56  
57  
58  
59  
60

ads, for instance), or if data collected with individuals did not relate to a clinical encounter with a primary care provider. For experimental studies, only patients from control or baseline groups were considered for analysis.

### *Data collected*

All data collected with patients enrolled in the included studies had been collected using self-administered paper-based questionnaires. From the baseline data (i.e. before-and-after or randomized controlled trial studies) we extracted the following characteristics of each study: year of data collection, study type, main objective of original study, clinical setting and types of decision(s) made by patients. For each study, we assessed patient characteristics such as sex, age (<45 years old,  $\geq$ 45 years old), professional status (full or part-time employment, no employment, retired), education (no postsecondary education, some postsecondary education), annual household income (<CAD \$60,000,  $\geq$ \$60,000), household size (living alone, living with at least one other person), marital status (married, single, separated/divorced, widowed), and whether the patient had a private drug insurance plan (yes, no). We also assessed clinical characteristics: whether this was the first encounter with that particular primary care provider (yes, no), whether the patient was accompanied during the encounter (yes, no), whether the decision was for a child (yes, no), patient preference for involvement in decision making (passive, active<sup>15 16</sup>), average annual frequency of consultations with any doctor ( $\leq$ 3, >3), self-reported health status<sup>17</sup> (excellent/very good/good, or fair/poor), whether the patient received a drug prescription (yes, no).

### *Data analysis*

1  
2  
3 First, we computed CSDC as defined by a score of  $\geq 25/100$  on the DCS,<sup>3 4 14 18</sup> at which point  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

First, we computed CSDC as defined by a score of  $\geq 25/100$  on the DCS,<sup>3 4 14 18</sup> at which point decisional conflict is positively associated with decisional delay, departure from active treatment, decision regret, nervousness and a higher intention to sue physicians in cases of harms from treatment.<sup>3 4</sup> This is the threshold most commonly used to distinguish a harmless from a harmful level of decisional conflict.<sup>3 19 20</sup> The DCS consists of 16 items, each of which is measured on a 5-point Likert scale (1 = strongly agree to 5 = strongly disagree, treated as a 0-4 score). The mean score of all items is multiplied by 25 to give a score out of 100. Higher scores indicate higher levels of decisional conflict.<sup>21</sup> The DCS shows good psychometric properties (test-retest reliability coefficient: 0.81, Cronbach's alpha range: 0.78 – 0.92) and its French translation has been validated.<sup>22-25</sup> Second, we conducted complete-subject analyses of the prevalence and risk factors of CSDC individually for each dataset at the patient level. After deletion of missing data and removal of participants in experimental groups, patient characteristics were similar to those of the original study populations. In studies where clusters of patients were recruited under the same clinician and/or within the same clinic, we assessed the impact of a potential cluster effect at each level of analysis (clinician and/or clinic). For each dataset, we computed overall prevalence of CSDC and prevalence for each category of available variables stratified by sex. Logistic regression (backwards selection) was used to explore the independent association between CSDC and potential risk factors, including interaction terms with each variable and sex. All significant variables at  $\alpha \leq 0.10$  were kept in the final model. We defined statistical significance at  $\alpha \leq 0.10$  because this was an exploratory study. If we found a non-negligible cluster effect, we used a generalized estimation equation (PROC GENMOD) with binary logit outcome. Otherwise, logistic regression was used. We calculated the receiver operating

1  
2  
3 characteristic to estimate the models' performance. All analyses were conducted with SAS 9.3  
4  
5 (SAS Institute Inc., Cary, NC, USA).  
6  
7  
8  
9

## 10 RESULTS

### 11 *Description of included studies*

12  
13  
14  
15  
16  
17  
18  
19  
20 We estimated the prevalence of CSDC in the context of five different studies conducted in  
21  
22 primary care. Each of these studies was designed to address different issues, and each collected  
23  
24 quite different data. However, each study group had independently identified the need to  
25  
26 measure decisional conflict using the DCS.<sup>24</sup> The following is a short description of included  
27  
28 studies.  
29  
30  
31  
32  
33

34 The first study was a before-and-after trial conducted in Ontario to assess the impact of  
35  
36 implementing the Ottawa Decision Support Framework (ODSF) on correspondences between  
37  
38 patients' and physicians' decisional conflict scores. Implementation of the framework consisted  
39  
40 of an interactive workshop, feedback, and a reminder at the point of care. Secondary objectives  
41  
42 were to evaluate the barriers and facilitators to implementation of the ODSF in primary care  
43  
44 practices and examine changes in physicians' intention to adopt the DSC.<sup>26</sup>  
45  
46  
47  
48  
49

50 The second study evaluated decisional conflict in the context of prenatal screening for Down  
51  
52 syndrome (GENETIC). This cross-sectional survey conducted with patients from Quebec  
53  
54 assessed the willingness of women and their family physicians to engage in shared decision-  
55  
56  
57  
58  
59  
60

1  
2  
3 making about prenatal Down-syndrome screening and factors that might influence this  
4 willingness.<sup>27</sup>  
5  
6  
7

8  
9  
10 The third study evaluated the impact of a training program for physicians (DECISION+)<sup>28</sup>. This  
11 pilot randomized controlled trial conducted in Quebec integrated multiple educational/behavioral  
12 change components that aimed to promote shared decision making about treatment options and  
13 specifically about the use of antibiotics for acute respiratory infections.<sup>28</sup>  
14  
15  
16  
17

18  
19  
20 The goal of the fourth study was to assess the psychometric properties of dyadic measures for  
21 shared decision making research. The study used a shared decision-making model (EXACKTE2)  
22 to explore how patients and clinicians influence one another. This cross-sectional study  
23 conducted in 17 primary care clinics in Ontario and Quebec explored the mutual influence  
24 between patients and physicians during consultations.<sup>29</sup>  
25  
26  
27

28  
29  
30 The last study used data gathered during a pilot study<sup>28</sup> to establish the feasibility of conducting  
31 the DECISION+ training program on a larger scale. The program was improved and renamed  
32 DECISION+2<sup>30</sup> before the definitive trial. This randomized controlled trial conducted in Quebec  
33 assessed the impact of DECISION+2 on antibiotics use for acute respiratory infections.  
34  
35  
36

37  
38  
39 Table 1 presents the characteristics of the included studies and their related datasets alongside the  
40 available independent variables.<sup>26-30</sup> All datasets were from projects conducted between 2003  
41 and 2010. Three were conducted in the province of Quebec, one was conducted in Ontario and  
42 one was conducted jointly by teams from Ontario and Quebec.<sup>29</sup> Of the five datasets available,  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 two were clustered randomized trials (DECISION+<sup>28</sup>, DECISION+2<sup>30</sup>), two were cross-sectional  
4 surveys (GENETIC<sup>27</sup>, EXACKTE2<sup>29</sup>) and one was a before-and-after trial (iODSF<sup>26</sup>). Decisions  
5  
6 were about undergoing a prenatal Down syndrome genetic screening test (GENETIC<sup>27</sup>), taking  
7  
8 antibiotics to treat acute respiratory infections (DECISION+<sup>28</sup>, DECISION+2<sup>30</sup>) and various  
9  
10 other primary care decisions (iODSF<sup>26</sup>, EXACKTE2<sup>29</sup>). Altogether, data from 1,338 primary  
11  
12 care patients were analyzed. Patients were aged between 15 and 83 years old and 69% were  
13  
14 female.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1:** Characteristics of datasets

Characteristics	Dataset				
	iODSF <sup>26</sup>	GENETIC <sup>27</sup>	DECISION+ <sup>28</sup>	EXACKTE2 <sup>29</sup>	DECISION+2 <sup>30</sup>
<b>Year of data collection</b>	2003	2007	2007	2009	2010
<b>Study type</b>	Before and after trial	Cross-sectional survey	Cluster randomized trial	Cross-sectional survey	Cluster randomized trial
<b>Main objective of study</b>	To assess the impact of implementing the Ottawa Decision Support Framework on correspondences between patients' and physicians' decisional conflict scores.	To assess the willingness of women and their family physicians to engage in shared decision making about prenatal Down-syndrome screening and the factors that might influence this willingness.	To develop, adapt and validate a shared decision making training program and estimate its impact on the decision of family physicians and their patients about whether to use antibiotics for ARIs.	To assess the psychometric properties of dyadic measures for shared decision making research.	To evaluate the effect of a shared decision making training program on decisions of family physicians and their patients about whether to use antibiotics for ARIs.
<b>Clinical setting</b>	5 FPTUs in the Quebec City area	3 FPTUs in the Quebec City area	4 family medicine groups in the Quebec City area	17 primary care clinics in the Quebec City area and in Ontario	9 FPTUs in the province of Quebec
<b>Type of decision</b>	Various other primary care decisions	To do a prenatal test or not	To take antibiotics or not for treating ARIs	Various other primary care decisions	To take antibiotics or not for treating ARIs
<b>Total participants (N)</b>	370	130	225	198	415
<b>Women; n (%)</b>	234 (63)	130 (100)	154 (68)	131 (66)	277 (67)
<b>Aged ≥ 45 years old; n(%)</b>	209 (56)	0 (0)	60 (27)	117 (59)	164 (40)
<b>Living by themselves; n(%)</b>	119 (32)	1 (1)	39 (17)	42 (21)	74 (18)
<b>Professional status; n(%)</b>					
- Employed full- or part-time	185 (50)	105 (81)	176 (78)	109 (55)	318 (77)
- Unemployed	69 (19)	25 (19)	36 (16)	30 (15)	65 (16)
- Retired	116 (31)	0 (0)	13 (6)	59 (30)	32 (8)
<b>Household income ≥ \$ 60,000; n (%)</b>	97 (26)	62 (48)	87 (39)	24 (12)	194 (47)
<b>Available variables</b>	Age, sex, employment status, education, annual income, household size, first encounter with that doctor	Age, sex, employment status, education, annual income, household size	Age, sex, employment status, education, annual income, household size, first encounter with that doctor, patient preference for involvement in decision making, self-reported health status, whether making a decision for a child, whether patient receives a prescription, whether patient has a private drug insurance plan	Age, sex, employment status, education, annual income, household size, marital status, average annual frequency of physician visits, first encounter with that doctor, patient is alone or accompanied	Age, sex, employment status, education, annual income, household size, first encounter with that doctor, patient preference for involvement in decision making, self-reported health status, whether making a decision for a child, whether patient receives a prescription, whether patient has a private drug insurance plan

FPTU: Family practice teaching unit; ARIs: Acute respiratory infections

1  
2  
3 *Prevalence of clinically significant decisional conflict*  
4  
5  
6  
7

8 Table 2 shows the prevalence of CSDC across all five datasets stratified by sex for available  
9 variables, since sex was found to be a modifying factor for at least one variable in four datasets.  
10 Prevalence ranged between 10.3% (iODSF<sup>26</sup>) (95% confidence intervals [CI]: 7.2 – 13.4) and  
11 31.1% (DECISION+2<sup>30</sup>) (95%CI: 26.6 – 35.6). CSDC was consistently more prevalent in males  
12 (4/4 studies), people aged 45 or older (4/4 studies), people living alone (4/5 studies), retirees (4/4  
13 studies), people preferring active participation in decision making (2/2 studies), people reporting  
14 poor health status (2/2 studies), people making the decision for themselves as opposed to for  
15 their children (2/2 studies), and people who did not have a private drug insurance plan (2/2  
16 studies).  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Table 2:** Prevalence\* of clinically significant decisional conflict according to datasets and sex

	iODSF <sup>26</sup>			GENETIC <sup>27</sup>	DECISION+ <sup>28</sup>			EXACKTE2 <sup>29</sup>			DECISION+2 <sup>30</sup>		
	F	M	All	All†	F	M	All	F	M	All	F	M	All
<b>Total participants (N)</b>	234	136	370	130	154	71	225	131	67	198	277	138	415
<b>Overall prevalence (95% confidence interval)</b>	7.7 (4.3; 11.1)	14.7 (8.7; 20.7)	10.3 (7.2; 13.4)	16.9 (10.4; 23.5)	17.5 (11.5; 23.6)	31.0 (20.0; 42.0)	21.8 (16.3; 27.2)	15.3 (9.0; 21.5)	28.4 (17.3; 39.4)	19.7 (14.1; 25.3)	28.5 (23.2; 33.9)	36.2 (28.1; 44.4)	31.1 (26.6; 35.6)
<b>Sociodemographic characteristics</b>													
<b>Age</b>													
< 45 years old	6.1	13.0	8.1	16.9	11.5	27.0	16.4	10.9	17.7	12.4	26.0	29.2	26.9
≥ 45 years old	9.2	15.6	12.0	N/A	34.2	42.1	36.7	19.4	32.0	24.8	36.2	50.0	41.5
<b>Professional status</b>													
Full- or part-time employment	9.3	14.9	11.4	18.1	17.7	28.1	21.0	10.8	25.7	15.6	27.6	37.0	30.8
No employment	6.0	0.0	4.4	12.0	11.5	50.0	22.2	18.2	25.0	20.0	29.8	27.8	29.2
Retired	6.1	20.0	12.1	N/A	33.3	25.0	30.8	22.9	33.3	27.1	35.0	41.7	37.5
<b>Education</b>													
No postsecondary education	5.9	14.4	9.1	9.8	16.0	34.7	23.4	26.0	21.4	24.4	26.3	33.3	28.9
At least some postsecondary education	11.1	15.2	12.6	21.5	19.0	22.7	19.8	8.7	33.3	16.7	29.4	37.8	32.1
<b>Annual household income</b>													
< \$60,000	5.1	13.3	8.1	17.7	14.1	41.3	23.2	15.0	24.1	17.8	32.3	30.3	31.7
≥ \$60,000	15.3	18.4	16.5	16.1	22.6	12.0	19.5	18.2	46.1	33.3	23.8	41.7	30.4
<b>Household size</b>													
Living alone	9.2	23.3	14.3	0.0	31.8	47.1	38.5	25.0	36.4	31.0	42.9	40.0	41.9
Living with ≥ 1 other person	7.0	10.8	8.4	17.1	15.2	25.9	18.3	13.5	24.4	16.7	25.4	35.4	28.7
<b>Marital status</b>													
Married								9.3	25.0	13.9			
Single								25.0	27.8	26.2			
Separated /divorced								33.3	44.4	38.1			
Widowed								22.2	25.0	23.1			
<b>Private drug insurance plan</b>													
Yes					17.5	26.0	20.1				26.3	35.6	29.4
No					17.5	42.9	26.2				34.2	37.8	35.3

F = Female; M = Male; N/A = Not applicable; \* Prevalence of Clinically Significant Decisional Conflict was defined as a score ≥ 25/100 on the Decisional Conflict Scale<sup>14</sup>; †In the GENETIC study, all participants were female.

**Table 2:** Prevalence\* of clinically significant decisional conflict according to datasets and sex (continuation)

Clinical characteristics	iODSF <sup>26</sup>			GENETIC <sup>27</sup>	DECISION+ <sup>28</sup>			EXACKTE2 <sup>29</sup>			DECISION+2 <sup>30</sup>		
	F	M	All	All†	F	M	All	F	M	All	F	M	All
<b>First encounter with that particular doctor</b>													
Yes	8.5	18.6	12.8		12.5	31.8	17.4	17.8	36.4	23.5	32.6	25.9	30.1
No	7.4	12.9	9.3		21.1	31.6	24.5	15.7	24.4	18.4	27.7	38.7	31.3
<b>Patient accompanied during encounter</b>													
Yes								11.1	33.3	18.5			
No								15.9	27.6	19.9			
<b>Decision for a child</b>													
Yes					10.0	31.2	15.2				22.9	30.0	25.0
No					21.2	30.9	24.5				30.4	38.0	33.0
<b>Patient preference for involvement</b>													
Passive					15.2	30.4	20.3				27.8	26.7	27.3
Active					21.0	32.0	24.1				28.6	37.4	31.4
<b>Average annual frequency of physician visits</b>													
≤ 3 average physician visits per year								9.9	39.4	19.2			
> 3 average physician visits per year								21.7	17.7	20.2			
<b>Self-reported health status</b>													
Excellent, very good, good					16.7	27.4	19.9				27.5	32.8	29.2
Fair, poor					30.0	55.6	42.1				40.9	69.2	51.4
<b>Patient received a prescription</b>													
Yes					16.4	32.8	21.7				29.5	34.6	31.1
No					23.1	20.0	22.2				24.5	42.9	30.9

F = Female; M = Male; N/A: Not applicable; \* Prevalence of Clinically Significant Decisional Conflict was defined as a score  $\geq 25/100$  on the Decisional Conflict Scale<sup>14</sup>; †In GENETIC study, all participants were female.

1  
2  
3 *Risk factors of clinically significant decisional conflict*  
4  
5  
6  
7

8 The impact of cluster effect at the clinician level was found to be negligible in all datasets.  
9  
10 However, we found a cluster effect at the clinic level in three projects (iODSF<sup>26</sup>, DECISION+<sup>28</sup>,  
11 DECISION+2<sup>30</sup>). Table 3 presents the multivariable regression analysis of the association  
12  
13 between CSDC and its potential independent risk factors. Sex was found to be a modifying factor  
14  
15 for at least one variable in all datasets (except GENETIC<sup>27</sup>, as all participants were women) and  
16  
17 an independent risk factor in one (EXACKTE2<sup>29</sup>). Living alone was positively associated with  
18  
19 CSDC in three out of four datasets (iODSF<sup>26</sup>, DECISION+<sup>28</sup>, DECISION+2<sup>30</sup>). Being aged 45 or  
20  
21 older was also positively associated with CDSC in three out of four datasets (DECISION+<sup>28</sup>,  
22  
23 EXACKTE2<sup>29</sup>, DECISION+2<sup>30</sup>) and there was a significant interaction with sex in one dataset  
24  
25 (iODSF<sup>26</sup>). An annual income above or equal to CAD \$60,000 was positively associated with  
26  
27 CSDC in two of the five datasets (iODSF<sup>26</sup>, EXACKTE2<sup>29</sup>) and we observed an interaction term  
28  
29 with sex in one dataset (DECISION+<sup>28</sup>). Other study variables were not significantly associated  
30  
31 with CSDC in more than one study.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 3:** Association between clinically significant decisional conflict and potential risk factors according to dataset

Potential risk factors	Dataset									
	iODSF <sup>26</sup>		GENETIC <sup>27</sup>		DECISION+ <sup>28</sup>		EXACKTE2 <sup>29</sup>		DECISION+2 <sup>30</sup>	
	$\beta \pm SE$	<i>p</i> -value	$\beta \pm SE$	<i>p</i> -value	$\beta \pm SE$	<i>p</i> -value	$\beta \pm SE$	<i>p</i> -value	$\beta \pm SE$	<i>p</i> -value
Sex (being male)	-0.54 ± 0.58	0.36	n = 0		-0.35 ± 0.56	0.54	1.45 ± 0.56	<b>0.01</b>	0.39 ± 0.25	0.11
Postsecondary education	-		0.93 ± 0.54	0.08	-		-0.79 ± 0.43	0.07	-	
Age (≥45)	0.66 ± 0.57	0.25	n = 0		1.02 ± 0.24	<b>&lt; 0.0001</b>	0.57 ± 0.45	0.09	0.61 ± 0.18	<b>&lt; 0.001</b>
Age (≥45) x sex	1.40 ± 0.39	<b>&lt; 0.001</b>	N/A		-		-		-	
Living alone	1.01 ± 0.23	<b>&lt; 0.0001</b>	n = 1		0.81 ± 0.25	<b>&lt; 0.01</b>	-		0.40 ± 0.17	0.02
Making the decision for a child (vs. for self)	N/A		N/A		-0.73 ± 0.39	0.06	N/A		-	
Making the decision for a child (vs. for self) x sex	N/A		N/A		1.20 ± 0.19	<b>&lt; 0.0001</b>	N/A		-	
Having received a prescription	N/A		N/A		-0.66 ± 0.25	<b>&lt; 0.01</b>	N/A		-	
Having received a prescription x sex	N/A		N/A		1.93 ± 0.10	<b>&lt; 0.0001</b>	N/A		-	
Annual family income ≥ \$60K	1.16 ± 0.13	<b>&lt; 0.0001</b>	-		1.19 ± 0.24	<b>&lt; 0.0001</b>	1.11 ± 0.56	<b>0.05</b>	-	
Annual family income ≥ \$60K x sex	-		N/A		-2.54 ± 0.69	<b>&lt; 0.001</b>	-		-	
Being unemployed	-0.89 ± 0.31	<b>&lt; 0.01</b>	-		-		-		0.15 ± 0.42	0.71
Being unemployed x sex	-		N/A		-		-		-0.98 ± 0.22	<b>&lt; 0.0001</b>
Retirement	-0.86 ± 0.44	<b>0.05</b>	n = 0		-		-		-0.34 ± 0.49	0.49
Being retired x sex	1.83 ± 0.69	<b>&lt; 0.01</b>	N/A		-		-		0.16 ± 0.76	0.83
Being single (vs. being married)	N/A		N/A		N/A		1.16 ± 0.54	<b>0.03</b>	N/A	
Being separated or divorced (vs. being married)	N/A		N/A		N/A		0.22 ± 0.74	0.76	N/A	
Self-reported health status “Excellent”, “Very good” or “good”	N/A		N/A		-		N/A		-0.95 ± 0.28	<b>&lt; 0.001</b>
Consulting a physician > 3 times a year	N/A		N/A		N/A		0.39 ± 0.55	0.48	N/A	
Consulting a physician > 3 times a year x sex	N/A		N/A		N/A		-1.92 ± 0.81	<b>0.02</b>	N/A	
<b>ROC</b>	<b>0.73</b>		<b>0.60</b>		<b>0.76</b>		<b>0.75</b>		<b>0.62</b>	

$\beta$  = Regression coefficient; SE = Standard error; N/A = Not available; ROC = Receiver operating characteristic

## DISCUSSION

Using data on 1338 patients from five studies conducted in primary care contexts in two Canadian provinces, Quebec and Ontario, we observed that the prevalence of CSDC in patients, defined as a score of  $\geq 25/100$  on the DCS, was substantial and varied across studies ranging from 10% to 31%. Populations at risk of CSDC included males, people living alone and people aged 45 years or older. To the best of our knowledge, this is the first account of the prevalence of CSDC as reported in studies conducted exclusively in primary care and with this many unique clinical encounters. None of the earlier studies measuring CSDC in a primary care clinical context focused on a decision dealt with entirely at the primary care level.<sup>31-34</sup> Our results lead us to make four main observations.

First, our results contradict a common belief that primary care only deals with mundane types of decision that involve no risk, loss, regret, or challenges to personal life values, and that primary care decisions therefore involve no personal uncertainty. Clearly, this is not how patients enrolled in these five studies saw it. Given the harmful downstream effects of unresolved CSDC, our results suggest that a significant number of primary care patients would benefit greatly from patient decision aids,<sup>11</sup> decision coaching<sup>35</sup> or from their healthcare providers being trained in shared decision making. These clinical approaches are known to be effective in resolving CSDC.<sup>36</sup>

Second, we observed a higher prevalence of CSDC in men than in women in all four datasets that included men and women. Moreover, sex was found to be an independent risk factor in one

1  
2  
3 dataset and significantly interacted with at least one variable in all datasets. This may be  
4 explained by the fact that more women than men consult primary care providers over their  
5 lifetime.<sup>37</sup> Women tend to consult healthcare providers more frequently due to their  
6 gynecological and obstetrical needs and also because they are often involved in health-related  
7 decision making for other family members.<sup>37 38</sup> Furthermore, physicians are known to discuss  
8 therapeutic and preventive interventions more often with women than with men.<sup>39</sup> Together,  
9 more visits to physicians and more discussion with them may contribute to a higher sense of self-  
10 efficacy among women about engaging in decision making.<sup>40</sup> This in turn could reduce CSDC in  
11 women.<sup>40</sup> As in earlier studies on the impact of sex on outcomes, our results highlight a  
12 significant effect of sex on CSDC and suggest that primary care providers should tailor their  
13 decision-making approach to the patient's sex.<sup>41</sup>

14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32 Third, people reporting living alone showed a consistently higher prevalence of CSDC than  
33 people reporting living with at least one other person. This is congruent with the theory  
34 underlying the DCS.<sup>24</sup> The higher prevalence of CSDC in people reporting living alone could be  
35 due to a lack of social support when they face health-related decisions, one of the key  
36 contributors to CSDC.<sup>5</sup> During the clinical encounter, primary care providers should explore the  
37 patient's social support systems, i.e. whether he/she can 1) check other people's opinions, 2)  
38 focus on those whose opinions matter most (physician, family, and friends) and 3) handle diverse  
39 sources of pressure.<sup>42</sup> Such support-clarification exercises help patients understand other  
40 perspectives and gather opinions about what other people would do if they were in the same  
41 situation. Our results suggest that lack of support for people living alone may aggravate CSDC in  
42 primary care patients. Although the contribution of family members is increasingly recognized as  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 an important source of social support for patients facing health decisions,<sup>43</sup> the literature has still  
4 not adequately addressed its full impact on decision making.<sup>44</sup> Primary care providers should pay  
5 closer attention to their patients living alone in their efforts to detect CSDC during the decision  
6 making process.  
7  
8  
9  
10

11  
12  
13  
14  
15 Lastly, patients aged 45 or older showed a higher prevalence of CSDC in all relevant datasets. As  
16 older adults tend to seek less information when making a decision, defer the decision more often,  
17 and are generally more risk avoidant than young adults, they may be more at risk of CSDC.<sup>45</sup> In  
18 addition, an enduring myth is that older and more vulnerable patients are less interested in  
19 participating in decision making with their healthcare providers than are less vulnerable  
20 patients.<sup>46</sup> Any and all of these reasons may contribute to the higher prevalence of CSDC  
21 observed in populations aged 45 years or older and should inform clinicians and researchers of  
22 the urgent need to foster the participation of older patients in decision making with the  
23 appropriate strategies.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38

39 Our study has some limitations. First, measuring CSDC was not the primary objective of any of  
40 the selected studies. Also, potentially relevant variables such as marital status or self-reported  
41 health status were missing in some datasets, and therefore we could not draw conclusions  
42 relating to these variables. Furthermore, a meta-analysis was not possible given the heterogeneity  
43 of the data sets (type of decision, study design, available variables). Nevertheless, the similar  
44 nature of the questionnaires in each study enabled us to compare associations in datasets  
45 independently from one another and thus assure external validity of the results.<sup>47</sup> Finally, we  
46 acknowledge that we cannot infer that our results are generalizable to the wider population as we  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 drew upon secondary analysis of existing datasets of studies conducted in specific primary care  
4 clinical contexts in two provinces in Canada. Further studies with appropriate survey methods  
5 and sampling frames could depict a more accurate portrait of CSDC in other primary care  
6 clinical contexts.  
7  
8  
9  
10  
11

## 12 13 14 15 **CONCLUSION**

16  
17  
18 We observed that the prevalence of CSDC in studies on decision making conducted in primary  
19 care contexts in two Canadian provinces, Quebec and Ontario, ranged from 10% to 31%. This  
20 prevalence varied depending on the type of decision and was higher in males, in people living  
21 alone, and in people aged 45 or older. Although we cannot generalize our results to the wider  
22 population, they should alert primary care providers to patients who may be at higher risk of  
23 CSDC. Training health professionals to identify CSDC in patients and ensuring that effective  
24 decision support interventions such as patient decision aids are implemented at the point of care  
25 should be encouraged to resolve CSDC.<sup>11 48</sup>  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## REFERENCES

1. Carpenito-Moyet L. Individual Nursing Diagnoses: Decisional Conflict. In: Carpenito-Moyet L, ed. *Nursing Diagnosis: Application to Clinical Practice*. 13 ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2010.
2. Janis I, Mann L. *Decision making: a psychological analysis of conflict, choice, and commitment*. New York: Free Press, 1977.
3. Knops AM, Goossens A, Ubbink DT, et al. Interpreting patient decisional conflict scores: behavior and emotions in decisions about treatment. *Med Decis Making* 2013;33:78-84 doi: 10.1177/0272989X12453500|.
4. Sun Q. Predicting Downstream Effects of High Decisional Conflict: Meta-analyses of the Decisional Conflict Scale. University of Ottawa, 2004.
5. O'Connor AM, Tugwell P, Wells GA, et al. A decision aid for women considering hormone therapy after menopause: decision support framework and evaluation. *Patient Educ Couns* 1998;33:267-79
6. Starfield B. *Primary Care. Balancing Health Needs, Services, and Technology*. Oxford: Oxford University Press, 1998.
7. Hsu C, Phillips WR, Sherman KJ, et al. Healing in primary care: a vision shared by patients, physicians, nurses, and clinical staff. *Ann Fam Med* 2008;6:307-14 doi: 10.1370/afm.838|.
8. Orasanu J, Connolly T. The reinvention of decision making. In: Klein G, Orasanu J, Calderwood R, Zsombok C, eds. *Decision making in action: models and methods*. Norwood, NJ: Ablex Publishing Corporation, 1993.
9. Braddock CH, 3rd. Supporting shared decision making when clinical evidence is low. *Medical care research and review* : MCCR 2013;70(1 Suppl):129S-40S doi: 10.1177/1077558712460280|.
10. Holzel LP, Kriston L, Harter M. Patient preference for involvement, experienced involvement, decisional conflict, and satisfaction with physician: a structural equation model test. *BMC Health Serv Res* 2013;13:231 doi: 10.1186/1472-6963-13-231.
11. Stacey D, Legare F, Col NF, et al. Decision aids for people facing health treatment or screening decisions. *The Cochrane Database Syst Rev* 2014;1:CD001431 doi: 10.1002/14651858.CD001431.pub4|.
12. Canada research chair in implementation of shared decision making in primary care. Practice-Based Research Network: Laboratory for the Implementation of Shared Decision Making in Primary Care. 2014. <http://www.decision.chaire.fmed.ulaval.ca/en/pbrn/>.
13. Muldoon LK, Hogg WE, Levitt M. Primary care (PC) and primary health care (PHC). What is the difference? *Can J Public Health* 2006;97(5):409-11
14. O'Connor A. User Manual - Decisional Conflict Scale. Secondary User Manual - Decisional Conflict Scale 2010 1993. [http://decisionaid.ohri.ca/docs/develop/User\\_Manuals/UM\\_Decisional\\_Conflict.pdf](http://decisionaid.ohri.ca/docs/develop/User_Manuals/UM_Decisional_Conflict.pdf).
15. Strull WM, Lo B, Charles G. Do patients want to participate in medical decision making? *JAMA : the journal of the American Medical Association* 1984;252(21):2990-4

16. Legare F, Guerrier M, Nadeau C, Rheaume C, Turcotte S, Labrecque M. Impact of DECISION + 2 on patient and physician assessment of shared decision making implementation in the context of antibiotics use for acute respiratory infections. *Implement Sci* 2013;8:144 doi: 10.1186/1748-5908-8-144.
17. Ware J, Jr., Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. *Med Care* 1996;34:220-33
18. Prevalence of Clinically Significant Decisional Conflict in Primary Care: A Scoping Review. International Shared Decision-making Conference 2013 16-19 Jun; Lima, Peru.
19. Ferron Parayre A, Labrecque M, Rousseau M, Turcotte S, Legare F. Validation of SURE, a four-item clinical checklist for detecting decisional conflict in patients. *Med Decis Making* 2014;34:54-62 doi: 10.1177/0272989X13491463.
20. Prevalence of Clinically Significant Decisional Conflict in Primary Care: A Scoping Review. International Shared Decision-Making Conference 2013, 16-19 Jun. Lima, Peru.
21. Le Collège des médecins de famille du Canada. La pratique de la médecine familiale: Le Centre de médecine de famille, 2011.
22. Kryworuchko J, Stacey D, Bennett C, Graham ID. Appraisal of primary outcome measures used in trials of patient decision support. *Patient Educ Couns* 2008;73:497-503 doi: 10.1016/j.pec.2008.07.011.
23. Mancini J, Santin G, Chabal F, Julian-Reynier C. Cross-cultural validation of the Decisional Conflict Scale in a sample of French patients. *Qual Life Res* 2006;15(6):1063-8 doi: 10.1007/s11136-005-6003-9.
24. O'Connor AM. Validation of a decisional conflict scale. *Med Decis Making* 1995;15:25-30
25. Joosten EA, DeFuentes-Merillas L, de Weert GH, Sensky T, van der Staak CP, de Jong CA. Systematic review of the effects of shared decision-making on patient satisfaction, treatment adherence and health status. *Psychother Psychosom* 2008;77:219-26 doi: 10.1159/000126073.
26. Legare F, O'Connor AM, Graham ID, Wells GA, Tremblay S. Impact of the Ottawa Decision Support Framework on the agreement and the difference between patients' and physicians' decisional conflict. *Med Decis Making* 2006;26:373-90 doi: 10.1177/0272989X06290492.
27. Legare F, St-Jacques S, Gagnon S, et al. Prenatal screening for Down syndrome: a survey of willingness in women and family physicians to engage in shared decision-making. *Prenat Diagn* 2011;31:319-26 doi: 10.1002/pd.2624.
28. Legare F, Labrecque M, LeBlanc A, et al. Training family physicians in shared decision making for the use of antibiotics for acute respiratory infections: a pilot clustered randomized controlled trial. *Health Expect* 2011;14 Suppl 1:96-110 doi: 10.1111/j.1369-7625.2010.00616.x.
29. Legare F, Turcotte S, Robitaille H, et al. Some but not all dyadic measures in shared decision making research have satisfactory psychometric properties. *J Clin Epidemiol* 2012;65:1310-20 doi: 10.1016/j.jclinepi.2012.06.019.
30. Giguere A, Legare F, Grimshaw J, et al. Printed educational materials: effects on professional practice and healthcare outcomes. *Cochrane Database Syst Rev* 2012;10:CD004398 doi: 10.1002/14651858.CD004398.pub3.
31. Arimori N. Randomized controlled trial of decision aids for women considering prenatal testing: The effect of the Ottawa Personal Decision Guide on decisional conflict. *Jpn J Nurs Sci* 2006;3:119-30.

- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
  - 47
  - 48
  - 49
  - 50
  - 51
  - 52
  - 53
  - 54
  - 55
  - 56
  - 57
  - 58
  - 59
  - 60
32. Kremer H, Ironson G, Schneiderman N, Hautzinger M. "It's my body": does patient involvement in decision making reduce decisional conflict? *Med Decis Making* 2007;27:522-32 doi: 10.1177/0272989X07306782.
33. McCaffery KJ, Irwig L, Chan SF, et al. HPV testing versus repeat Pap testing for the management of a minor abnormal Pap smear: evaluation of a decision aid to support informed choice. *Patient Educ Couns* 2008;73:473-9, 81 doi: 10.1016/j.pec.2008.07.021.
34. Montgomery AA, Emmett CL, Fahey T, et al. Two decision aids for mode of delivery among women with previous caesarean section: randomised controlled trial. *BMJ* 2007;334:1305 doi: 10.1136/bmj.39217.671019.55.
35. O'Connor AM, Stacey D, Legare F. Coaching to support patients in making decisions. *BMJ* 2008;336:228-9 doi: 10.1136/bmj.39435.643275.BE.
36. Legare F, Stacey D, Turcotte S, et al. Interventions for improving the adoption of shared decision making by healthcare professionals. *Cochrane Database Syst Rev* 2014;9:CD006732 doi: 10.1002/14651858.CD006732.pub3.
37. Wang Y, Hunt K, Nazareth I, Freemantle N, Petersen I. Do men consult less than women? An analysis of routinely collected UK general practice data. *BMJ Open* 2013;3(8):e003320 doi: 10.1136/bmjopen-2013-003320.
38. Scaife B, Gill P, Heywood P, Neal R. Socio-economic characteristics of adult frequent attenders in general practice: secondary analysis of data. *Fam Pract* 2000;17:298-304
39. Bertakis KD, Azari R. Patient gender and physician practice style. *J Women's Health* 2007;16:859-68 doi: 10.1089/jwh.2006.0170.
40. Joseph-Williams N, Elwyn G, Edwards A. Knowledge is not power for patients: a systematic review and thematic synthesis of patient-reported barriers and facilitators to shared decision making. *Patient Educ Couns* 2014;94:291-309 doi: 10.1016/j.pec.2013.10.031.
41. Bertakis KD. The influence of gender on the doctor-patient interaction. *Patient Educ Couns* 2009;76:356-60 doi: 10.1016/j.pec.2009.07.022.
42. O'Connor A, Joosten M. Decisional Conflict: Supporting People Experiencing Uncertainty about Options Affecting their Health. *Secondary Decisional Conflict: Supporting People Experiencing Uncertainty about Options Affecting their Health* 2007.  
[http://homeless.ehclients.com/images/uploads/W-2\\_Ottawa\\_Decision\\_Making\\_tool--Reading-1.pdf](http://homeless.ehclients.com/images/uploads/W-2_Ottawa_Decision_Making_tool--Reading-1.pdf).
43. Clayman ML, Morris MA. Patients in context: recognizing the companion as part of a patient-centered team. *Patient Educ Couns* 2013;91:1-2 doi: 10.1016/j.pec.2013.02.004.
44. Siminoff LA. Incorporating patient and family preferences into evidence-based medicine. *BMC medical informatics and decision making* 2013;13 Suppl 3:S6 doi: 10.1186/1472-6947-13-S3-S6.
45. Mather M. A Review of Decision-Making Processes: Weighing the Risks and Benefits of Aging. In: LL C, CR H, eds. *When I'm 64*. Washington, DC: National Academies Press (US), 2006.
46. Legare F, Thompson-Leduc P. Twelve myths about shared decision making. *Patient Educ Couns* 2014;96:281-6 doi: 10.1016/j.pec.2014.06.014.
47. Ioannidis JP. Why most published research findings are false. *PLoS Med* 2005;2:e124 doi: 10.1371/journal.pmed.0020124.
48. Towle A, Godolphin W. Framework for teaching and learning informed shared decision making. *BMJ* 1999;319(7212):766-71

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

BMJ Open: first published as 10.1136/bmjopen-2016-011490 on 28 June 2016. Downloaded from <http://bmjopen.bmj.com/> on April 27, 2024 by guest. Protected by copyright.

## PRISMA Checklist

### Prevalence of clinically significant decisional conflict: a pooled analysis of five studies on decision making in primary care

Philippe Thompson-Leduc, MSc  
Stéphane Turcotte, MSc  
Centre Hospitalier Universitaire de Québec Research Centre, Quebec City, Canada

Michel Labrecque, MD PhD CCMF FCMF  
France Légaré, MD PhD CCMF FCMF  
Titular Professors  
Department of Family Medicine and Emergency Medicine, Faculty of Medicine, Laval University, Quebec City, Canada  
Centre Hospitalier Universitaire de Québec Research Centre, Quebec City, Canada

Corresponding Author :  
France Légaré MD PhD CCMF FCMF  
Address : Centre Hospitalier Universitaire de Québec Research Centre, Quebec City, Canada, Hôpital St-François d'Assise, 10 rue Espinay, Quebec City, Quebec, Canada  
E-mail : [france.legare@mfa.ulaval.ca](mailto:france.legare@mfa.ulaval.ca)  
Phone : 418-525-4437  
Fax : 418-525-4194

Criteria		Page	Brief description of how the criteria were handled in the manuscript
<b>TITLE</b>			
1	Identify the report as a systematic review, meta-analysis, or both.	p. 1	“Prevalence of clinically significant decisional conflict: a pooled analysis of five studies on decision making in primary care”.
<b>ABSTRACT</b>			
2	Provide a structured summary including, as applicable: Background (research question and main objectives); Methods (data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods); Results (number and type of studies and participants, main outcomes with CI); Discussion (strengths and	pp. 4-5	<p><b>Objectives:</b> Unresolved clinically significant decisional conflict (CSDC) in patients following a consultation with a health professional is often the result of inadequate patient involvement in decision making and may result in poor outcomes. We sought to identify the prevalence of CSDC in studies on decision making in primary care contexts and to explore its risk factors.</p> <p><b>Setting:</b> We performed a secondary analysis of existing datasets from studies conducted in Primary Care Practice-Based Research</p>

	<p>limitations of the evidence, general interpretation and important implications) Other (report primary funding source, registration number)</p>		<p>Networks in Quebec and Ontario, Canada.</p> <p><b>Participants:</b> Eligible studies included a patient-reported measure on the 16-item Decisional Conflict Scale (DCS) following a decision made with a healthcare professional with no study design restriction.</p> <p><b>Primary and secondary outcome measures:</b> CSDC was defined as a score <math>\geq 25/100</math> on the DCS. The prevalence of CSDC was stratified by sex; and patient-level logistic regression analysis was performed to explore its potential risk factors. Datasets of studies were analyzed individually and qualitatively compared.</p> <p><b>Results:</b> Five projects conducted between 2003 and 2010 were included. They covered a range of decisions: prenatal genetic screening, antibiotics for acute respiratory infections and miscellaneous. They included a total of 1338 primary care patients (69% female; range of age: 15 to 83). The prevalence of CSDC in patients varied across studies and ranged from 10.3% (95% confidence interval: 7.2% – 13.4%) to 31.1% (95% confidence interval: 26.6% – 35.6%). Across the five studies, risk factors of CSDC included being male, living alone, and being 45 or older.</p> <p><b>Conclusions:</b> Prevalence of CSDC in patients who had enrolled in studies conducted in primary care contexts was substantial and appeared to vary according to the type of decision as well as to patient characteristics such as sex, living arrangement and age. Patients presenting risk factors of CSDC should be offered decision aids to increase their involvement in decision making.”</p>
<b>INTRODUCTION</b>			
3	<i>Rationale:</i> describe the rationale for the review in the context of what is already known.	p. 7	“When facing health-related decisions and presented with multiple options, patients are subject to uncertainty about what to choose. This uncertainty is known as decisional conflict. Decisional conflict is an intra-

			<p>personal psychological construct that is felt by individuals when facing decisions that involve risk, loss, regret, or challenges to personal life values. 1 2 In lay terms, decisional conflict reflects the level of comfort that an individual faces in making a decision. In some patients it may translate into clinically significant decisional conflict (CSDC), at which point decisional conflict is positively associated with decisional delay, departure from active treatment, decision regret, nervousness and a higher intention to sue physicians in cases of harms from treatment.3 4 Thus it is essential to identify patients experiencing CSDC, as there are several modifiable deficits that lead to CSDC, including 1) inadequate knowledge of options; 2) unclear values regarding harms and benefits of options; and 3) inadequate support or resources for decision making. These may all be addressed with effective decision support.”</p>
4	<i>Objectives:</i> provide an explicit statement of questions being addressed with reference to participants, intervention, comparisons, outcomes, and study design (PICOS)	p. 8	<p>“Analyzing (S) and comparing (C) the outcomes (O) of decision-making studies (I) among primary care patients (P) could thus have a beneficial impact on the quality of care for a large number of individuals. We sought to identify the prevalence of CSDC in studies conducted in primary care contexts and to explore its risk factors (<i>Objective</i>).”</p>
<b>METHODS</b>			Data extracted from each of the studies were relevant to the population characteristics, study design, exposure, outcome, and possible effect modifiers of the association.
5	<i>Protocol and registration</i>	N/A	There was no registered protocol, but the first author performed a protocol for this study in his masters degree.
6	<i>Eligibility criteria</i> (studies characteristics, the rationale for criteria should be stated)	pp. 8-9	<p>“Studies were included if 1) they were set entirely in primary care (defined as the patient’s point of entry into the healthcare system, most often consulting a family physician<sup>13</sup>); 2) they assessed patient-reported decisional conflict using the French or English version of the 16-item Decisional Conflict Scale (DCS)<sup>14</sup>; and 3) DCS scores were collected from patients following a clinical encounter with a primary care</p>

			provider. There was no study design restriction. Studies were excluded if data had been gathered in a specialized clinic, if participants were recruited from the public (through newspaper ads, for instance), or if data collected with individuals did not relate to a clinical encounter with a primary care provider. For experimental studies, only patients from control or baseline groups were considered for analysis.”
7	<i>Information sources</i> (details of hand searching with dates)	p. 8	“We carried out a secondary analysis of existing datasets from studies conducted within or in collaboration with the Laval University Primary Care Practice-Based Research Network (PBRN) in the Province of Quebec, Canada. This network comprises twelve family practice teaching units affiliated with Laval University and collaborates with other research networks nationally and internationally.”
8	<i>Search</i> (present the full electronic search strategy for at least one database)	N/A	Not applicable.
9	<i>Study selection</i> : State the process for determining which studies were eligible for inclusion (screening)	p. 8	“Studies were included if 1) they were set entirely in primary care (defined as the patient’s point of entry into the healthcare system, most often consulting a family physician <sup>13</sup> ); 2) they assessed patient-reported decisional conflict using the French or English version of the 16-item Decisional Conflict Scale (DCS) <sup>14</sup> ; and 3) DCS scores were collected from patients following a clinical encounter with a primary care provider. There was no study design restriction.”
10	<i>Data collection process</i> (extraction data independently in duplicate and any process for confirming these data with investigators)	p. 9	“From the baseline data (i.e. before-and-after or randomized controlled trial studies) we extracted the following characteristics of each study: year of data collection, study type, main objective of original study, clinical setting and types of decision(s) made by patients.”
11	<i>Data items</i> : describe how the information and variables to be collected were chosen. List and define all study level and	p. 9	“All data collected with patients enrolled in the included studies had been collected using self-administered paper-based questionnaires. From the baseline data (i.e. before-and-after or



	<p>participant level, including baseline and follow-up information. If applicable, describe methods of standardizing or translating variables within the datasets to ensure common scales or measurement across studies (list and define all variables for which data were sought)</p>		<p>randomized controlled trial studies) we extracted the following characteristics of each study: year of data collection, study type, main objective of original study, clinical setting and types of decision(s) made by patients. For each study, we assessed patient characteristics such as sex, age (&lt;45 years old, ≥45 years old), professional status (full or part-time employment, no employment, retired), education (no postsecondary education, some postsecondary education), annual household income (&lt;CAD \$60,000, ≥\$60,000), household size (living alone, living with at least one other person), marital status (married, single, separated/divorced, widowed), and whether the patient had a private drug insurance plan (yes, no). We also assessed clinical characteristics: whether this was the first encounter with that particular primary care provider (yes, no), whether the patient was accompanied during the encounter (yes, no), whether the decision was for a child (yes, no), patient preference for involvement in decision making (passive, active[15 16]), average annual frequency of consultations with any doctor (≤3, &gt;3), self-reported health status[17] (excellent/very good/good, or fair/poor), whether the patient received a drug prescription (yes, no).”</p>
<p>12</p>	<p><i>Risk of bias in individual studies:</i> Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), report if and how this information is to be used in any data synthesis.</p>	<p>N/A</p>	<p>Not applicable.</p>
<p>13</p>	<p><i>Summary measures:</i> State all outcomes addressed and define them in detail, and whether they were primary or secondary outcomes. Give the principal measures of effect (e.g., risk ratio, difference in means) used for each outcome.</p>	<p>p. 10</p>	<p>“First, we computed CSDC as defined by a score of ≥25/100 on the DCS,[3 4 14 18] at which point decisional conflict is positively associated with decisional delay, departure from active treatment, decision regret, nervousness and a higher intention to sue physicians in cases of harms from treatment. [3 4] This is the threshold most commonly</p>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

			used to distinguish a harmless from a harmful level of decisional conflict. [3 19 20] The DCS consists of 16 items, each of which is measured on a 5-point Likert scale (1 = strongly agree to 5 = strongly disagree, treated as a 0-4 score). The mean score of all items is multiplied by 25 to give a score out of 100. Higher scores indicate higher levels of decisional conflict.[21] The DCS shows good psychometric properties (test-retest reliability coefficient: 0.81, Cronbach's alpha range: 0.78 – 0.92) and its French translation has been validated.[22-25]"
14	<p><i>Synthesis of results:</i> Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I<sup>2</sup>) for each meta-analysis. How effect estimates were generated separately within each study and combined across studies (where applicable). How missing data within studies were dealt. Estimation of interactions. Potential effect modifiers.</p>	p. 10	<p>"Second, we conducted complete-subject analyses of the prevalence and risk factors of CSDC individually for each dataset at the patient level. After deletion of missing data and removal of participants in experimental groups, patient characteristics were similar to those of the original study populations. In studies where clusters of patients were recruited under the same clinician and/or within the same clinic, we assessed the impact of a potential cluster effect at each level of analysis (clinician and/or clinic). For each dataset, we computed overall prevalence of CSDC and prevalence for each category of available variables stratified by sex. Logistic regression (backwards selection) was used to explore the independent association between CSDC and potential risk factors, including interaction terms with each variable and sex. All significant variables at <math>\alpha \leq 0.10</math> were kept in the final model. We defined statistical significance at <math>\alpha \leq 0.10</math> because this was an exploratory study. If we found a non-negligible cluster effect, we used a generalized estimation equation (PROC GENMOD) with binary logit outcome. Otherwise, logistic regression was used. We calculated the receiver operating characteristic to estimate the models' performance. All analyses were conducted with SAS 9.3 (SAS Institute Inc., Cary, NC, USA)."</p>
15	<p><i>Risk of bias across studies:</i> Specify any assessment of risk</p>	N/A	Not applicable

	of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).		
16	<i>Additional analyses:</i> Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	p. 10	All methods have been described in point 13 and 14.
<b>RESULTS</b>			
17	<i>Study selection:</i> Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram	pp. 11-12	We included a before-and-after study, two cross-sectional studies, and two randomized studies.
18	<i>Study characteristics:</i> For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	pp12-13	“Table 1 presents the characteristics of the included studies and their related datasets alongside the available independent variables.[26-30] All datasets were from projects conducted between 2003 and 2010. Three were conducted in the province of Quebec, one was conducted in Ontario and one was conducted jointly by teams from Ontario and Quebec.[29] Of the five datasets available, two were clustered randomized trials (DECISION+[28], DECISION+2[30]), two were cross-sectional surveys (GENETIC[27], EXACKTE2[29]) and one was a before-and-after trial (iODSF[26]). Decisions were about undergoing a prenatal Down syndrome genetic screening test (GENETIC[27]), taking antibiotics to treat acute respiratory infections (DECISION+[28], DECISION+2[30]) and various other primary care decisions (iODSF[26], EXACKTE2[29]). Altogether, data from 1,338 primary care patients were analyzed. Patients were aged between 15 and 83 years old and 69% were female.”
19	<i>Risk of bias within studies:</i> Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	N/A	Not applicable.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26	20	<i>Results of individual studies:</i> For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	pp. 16-17	95% confidence intervals are presented with all individual estimates in Table 2: “Table 2 shows the prevalence of CSDC across all five datasets stratified by sex for available variables, since sex was found to be a modifying factor for at least one variable in four datasets. Prevalence ranged between 10.3% (iODSF[26]) (95% confidence intervals [CI]: 7.2 – 13.4) and 31.1% (DECISION+2[30]) (95%CI: 26.6 – 35.6). CSDC was consistently more prevalent in males (4/4 studies), people aged 45 or older (4/4 studies), people living alone (4/5 studies), retirees (4/4 studies), people preferring active participation in decision making (2/2 studies), people reporting poor health status (2/2 studies), people making the decision for themselves as opposed to for their children (2/2 studies), and people who did not have a private drug insurance plan (2/2 studies).”
27 28 29 30 31 32	21	<i>Synthesis of results:</i> Present results of each meta-analysis done, including confidence intervals and measures of consistency.	N/A	Not applicable.
33 34 35 36 37	22	<i>Risk of bias across studies:</i> Present results of any assessment of risk of bias across studies (see Item 15).	N/A	Not applicable.
38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	23	<i>Additional analysis:</i> Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	p. 19	Table 3 present results of association testing with p-values for each dataset:  “The impact of cluster effect at the clinician level was found to be negligible in all datasets. However, we found a cluster effect at the clinic level in three projects (iODSF[26], DECISION+[28], DECISION+2[30]). Table 3 presents the multivariable regression analysis of the association between CSDC and its potential independent risk factors. Sex was found to be a modifying factor for at least one variable in all datasets (except GENETIC[27], as all participants were women) and an independent risk factor in one (EXACKTE2[29]). Living alone was positively associated with CSDC in three out of four datasets (iODSF[26],

			DECISION+[28], DECISION+2[30]). Being aged 45 or older was also positively associated with CSDC in three out of four datasets (DECISION+[28], EXACKTE2[29], DECISION+2[30]) and there was a significant interaction with sex in one dataset (iODSF[26]). An annual income above or equal to CAD \$60,000 was positively associated with CSDC in two of the five datasets (iODSF[26], EXACKTE2[29]) and we observed an interaction term with sex in one dataset (DECISION+[28]). Other study variables were not significantly associated with CSDC in more than one study.”
<b>DISCUSSION</b>			
24	<i>Summary of evidence:</i> Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	p. 20	“Using data on 1338 patients from five studies conducted in primary care contexts in two Canadian provinces, Quebec and Ontario, we observed that the prevalence of CSDC in patients, defined as a score of $\geq 25/100$ on the DCS, was substantial and varied across studies ranging from 10% to 31%. Populations at risk of CSDC included males, people living alone and people aged 45 years or older. ... Given the harmful downstream effects of unresolved CSDC, our results suggest that a significant number of primary care patients would benefit greatly from patient decision aids,[11] decision coaching[35] or from their healthcare providers being trained in shared decision making. These clinical approaches are known to be effective in resolving CSDC.[36]” We discussed the more consistent risk factors of CSDC one by one.
25	<i>Strengths and Limitations:</i> Discuss strengths and limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	p. 22	“Measuring CSDC was not the primary objective of any of the selected studies. Also, potentially relevant variables such as marital status or self-reported health status were missing in some datasets, and therefore we could not draw conclusions relating to these variables. Furthermore, a meta-analysis was not possible given the heterogeneity of the data sets (type of decision, study design, available variables). Nevertheless, the similar nature of the questionnaires in each study

			<p>enabled us to compare associations in datasets independently from one another and thus assure external validity of the results.[47] Finally, we acknowledge that we cannot infer that our results are generalizable to the wider population as we drew upon secondary analysis of existing datasets of studies conducted in specific primary care clinical contexts in two provinces in Canada. Further studies with appropriate survey methods and sampling frames could depict a more accurate portrait of CSDC in other primary care clinical contexts.”</p>
26	<p><i>Conclusions:</i> Provide a general interpretation of the results in the context of other evidence, and implications for future research.</p>	p. 23	<p>“We observed that the prevalence of CSDC in studies on decision making conducted in primary care contexts in two Canadian provinces, Quebec and Ontario, ranged from 10% to 31%. This prevalence varied depending on the type of decision and was higher in males, in people living alone, and in people aged 45 or older. Although we cannot generalize our results to the wider population, they should alert primary care providers to patients who may be at higher risk of CSDC. Training health professionals to identify CSDC in patients and ensuring that effective decision support interventions such as patient decision aids are implemented at the point of care should be encouraged to resolve CSDC.[11 48].”</p>
<b>FUNDING</b>			
27	<p><i>Funding:</i> Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.</p>	p. 2	<p>“FL is Tier-2 Canada Research Chair in Implementation of Shared Decision Making in Primary Care.”</p>

# BMJ Open

## PREVALENCE OF CLINICALLY SIGNIFICANT DECISIONAL CONFLICT: AN ANALYSIS OF FIVE STUDIES ON DECISION MAKING IN PRIMARY CARE

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-011490.R1
Article Type:	Research
Date Submitted by the Author:	10-May-2016
Complete List of Authors:	Thompson-Leduc, Philippe; CHU de Quebec and Universite Laval, Population Health and Practice-Changing Research Group Turcotte, Stéphane; Chu de Québec, Population Health and Practice-Changing Research Group Labrecque, Michel; Universite Laval, Department of Family Medicine and Emergency Medicine; CHU de Québec, Population Health and Practice-Changing Research Group Legare, France; Laval University, Department of Family Medicine and Emergency Medicine; CHU de Québec, Population Health and Practice-Changing Research Group
<b>Primary Subject Heading</b>:	General practice / Family practice
Secondary Subject Heading:	Epidemiology, Patient-centred medicine
Keywords:	Decisional conflict, shared decision making, PRIMARY CARE

SCHOLARONE™  
Manuscripts

only

**TITLE:**

PREVALENCE OF CLINICALLY SIGNIFICANT DECISIONAL CONFLICT: AN  
ANALYSIS OF FIVE STUDIES ON DECISION MAKING IN PRIMARY CARE

**AUTHORS:**

Philippe THOMPSON-LEDUC<sup>1</sup>, Stéphane TURCOTTE<sup>1</sup>, Michel LABRECQUE<sup>1,2</sup>,  
France LÉGARÉ<sup>1,2</sup>

1. Population Health and Practice-Changing Research Group, Centre Hospitalier

Universitaire de Québec Research Centre, Quebec City, Canada

2. Department of Family Medicine and Emergency Medicine, Faculty of Medicine, Laval

University, Quebec City, Canada

**CORRESPONDING AUTHOR:**

France Légaré, MD, PhD, CCMF, FCMF

Centre Hospitalier Universitaire de Québec Research Centre

Hôpital St-François d'Assise

10, rue Espinay, Québec

Québec, Canada

Phone : 418 525-4437

Fax: 418 525-4194

[france.legare@mfa.ulaval.ca](mailto:france.legare@mfa.ulaval.ca)



**FUNDING STATEMENT:**

FL is Tier-2 Canada Research Chair in Implementation of Shared Decision Making in Primary Care.

**CONTRIBUTORS STATEMENT**

Conceived and designed the analysis plan: FL, ML, PTL, ST. Analyzed the data: FL, ML, PTL, ST. Wrote the paper: FL, PTL. Critically reviewed the manuscript for important intellectual content: FL, PTL, ML, ST. Read and approved the final version: FL, PTL, ML, ST. Guarantors: FL, PTL

**PRIOR PRESENTATION:**

This manuscript is original and is not being considered for publication elsewhere.

**WORD COUNT: 3853/4000**

**NUMBER OF TABLES, FIGURES, APPENDICES:**

Tables: 3

Figures: 0

Appendices: 0

**ABBREVIATIONS:**

CI: Confidence intervals

1  
2  
3 CSDC: Clinically Significant Decisional Conflict  
4

5 DCS: Decisional Conflict Scale  
6

7  
8 FPTU: Family Practice Teaching Unit  
9

10 OR: Odds ratio  
11

12 PBRN: Practice-based Research Network  
13  
14

15  
16  
17 **KEYWORDS (3):**  
18

19  
20 Decisional conflict, shared decision making, primary care  
21  
22

23  
24 **ACKNOWLEDGEMENTS:**  
25

26  
27 The authors wish to thank Louisa Blair for editing this manuscript.  
28  
29

30  
31 **CONFLICT OF INTEREST STATEMENT:**  
32

33  
34 The authors declare no conflict of interest.  
35  
36

37  
38 **DATA SHARING STATEMENT:**  
39

40  
41 No additional data are available.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**ABSTRACT (300/300 WORDS)**

**Objectives:** Unresolved clinically significant decisional conflict (CSDC) in patients following a consultation with health professionals is often the result of inadequate patient involvement in decision-making and may result in poor outcomes. We sought to identify the prevalence of CSDC in studies on decision-making in primary care and to explore its risk factors.

**Setting:** We performed a secondary analysis of existing datasets from studies conducted in Primary Care Practice-Based Research Networks in Quebec and Ontario, Canada.

**Participants:** Eligible studies included a patient-reported measure on the 16-item Decisional Conflict Scale (DCS) following a decision made with a healthcare professional with no study design restriction.

**Primary and secondary outcome measures:** CSDC was defined as a score  $\geq 25/100$  on the DCS. The prevalence of CSDC was stratified by sex; and patient-level logistic regression analysis was performed to explore its potential risk factors. Datasets of studies were analyzed individually and qualitatively compared.

**Results:** Five projects conducted between 2003 and 2010 were included. They covered a range of decisions: prenatal genetic screening, antibiotics for acute respiratory infections and miscellaneous. Altogether, the five projects gathered data from encounters with a

1  
2  
3 total of 1,338 primary care patients (69% female; range of age: 15 to 83). The prevalence  
4  
5 of CSDC in patients varied across studies and ranged from 10.3% (95% confidence  
6  
7 interval: 7.2% – 13.4%) to 31.1% (95% confidence interval: 26.6% – 35.6%). Across the  
8  
9 five studies, risk factors of CSDC included being male, living alone, and being 45 or  
10  
11 older.  
12  
13

14  
15  
16  
17 **Conclusions:** Prevalence of CSDC in patients who had enrolled in studies conducted in  
18  
19 primary care contexts was substantial and appeared to vary according to the type of  
20  
21 decision as well as to patient characteristics such as sex, living arrangement and age.  
22  
23 Patients presenting risk factors of CSDC should be offered tools to increase their  
24  
25 involvement in decision-making.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Strengths and limitations of this study

- This study included data on 1,338 patients from five studies conducted in primary care contexts in two Canadian provinces, Quebec and Ontario.
- To the best of our knowledge, this is the first account of the prevalence of CSDC as reported in studies conducted exclusively in primary care and with this many unique clinical encounters when combined.
- Our results contradict a common belief that primary care deals only with decisions involving no perception of risk, loss, or regret; our study also reports a higher prevalence of CSDC in men than women, in people living alone, and in older patients.
- The fact that measuring CSDC was not the primary objective of any of the selected studies could affect observed results.
- A meta-analysis was not possible given the heterogeneity of the data sets (type of decision, study design, available variables) and thus the difficulty associated with its interpretation.

## INTRODUCTION

When facing health-related decisions and presented with multiple options, patients are subject to uncertainty about what to choose. This uncertainty is known as decisional conflict. Decisional conflict is an intra-personal psychological construct that is felt by individuals when facing decisions that involve risk, loss, regret, or challenges to personal life values.<sup>1 2</sup> In lay terms, decisional conflict reflects the level of comfort that an individual faces in making a decision. In some patients it may translate into clinically significant decisional conflict (CSDC), at which point decisional conflict is positively associated with decisional delay, departure from active treatment, decision regret, nervousness and a higher intention to sue physicians in cases of harms from treatment.<sup>3 4</sup> Thus it is essential to identify patients experiencing CSDC, as there are several modifiable deficits that lead to CSDC, including 1) inadequate knowledge of options; 2) unclear values regarding harms and benefits of options; and 3) inadequate support or resources for decision making. These may all be addressed with effective decision support.<sup>5</sup> In primary care, the gateway to the healthcare system, decisional conflict is particularly relevant. The majority of healthcare problems are treated in primary care, providing care focused on the individual and his or her context for all but very uncommon or unusual conditions. Primary care physicians provide continuity of care and coordinate or integrate the care provided by other levels of the system or by other professionals.<sup>6</sup> A greater emphasis on primary care is expected to lower the costs of care, improve health and reduce inequalities in the sphere of population's health. However, primary care is also the context in which costly and harmful overuse of treatment or screening options is most prevalent, and therefore an area where decision-making requires urgent improvement. It is also a context in which the available evidence is often equivocal, goals are

1  
2  
3 often ill-defined, and decision-making is subject to structural, organizational and time  
4 pressures.<sup>7-9</sup> These difficulties can be addressed successfully with effective decision support.<sup>5</sup>  
5  
6 For example, patient decision aids have proven to be effective in reducing overuse of  
7  
8 inappropriate treatments<sup>10</sup>, and in resolving CSDC following the decision-making process.<sup>11 12</sup>  
9  
10 Analyzing and comparing the outcomes of studies measuring decisional conflict among primary  
11  
12 care patients could thus have a widespread impact on implementations to support optimal  
13  
14 healthcare decisions and lead to improvement in quality of care for a large number of  
15  
16 individuals. We therefore explored the magnitude of this phenomenon by determining the  
17  
18 prevalence of CSDC in studies conducted in primary care contexts and their risk factors.  
19  
20  
21  
22  
23  
24  
25  
26

## 27 **METHODS**

### 28 *Source of data and participants*

29  
30  
31  
32 We carried out a secondary analysis of existing datasets from studies conducted within or in  
33  
34 collaboration with the Laval University Primary Care Practice-Based Research Network (PBRN)  
35  
36 in the Province of Quebec, Canada. This network comprises twelve family practice teaching  
37  
38 units affiliated with Laval University and collaborates with other research networks nationally  
39  
40 and internationally.<sup>13</sup> We screened the Laval University PBRN for potentially eligible studies  
41  
42 and considered all patient data gathered from five eligible studies. Studies were included if 1)  
43  
44 they were set entirely in primary care (defined as the patient's point of entry into the healthcare  
45  
46 system, most often consulting a family physician<sup>14</sup>); 2) they assessed patient-reported decisional  
47  
48 conflict using the French or English version of the 16-item Decisional Conflict Scale (DCS) (i.e.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 studies conducted after the development of the DCS in 1993);<sup>15</sup> and 3) DCS scores were  
4 collected from patients following a clinical encounter with a primary care provider. There was no  
5 study design restriction. Studies were excluded if data had been gathered in a specialized clinic,  
6 if participants were recruited from the public (through newspaper ads, for instance), or if data  
7 collected with individuals did not relate to a clinical encounter with a primary care provider. For  
8 experimental studies, only patients from control or baseline groups were considered for analysis.  
9 “Each of the projects from which data were extracted had been granted ethical approval by its  
10 respective institution. For this secondary analysis, all nominal data were redacted and none of the  
11 variables could be associated with individuals. Therefore further ethics approval was not  
12 required.”  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

### 29 *Data collected*

30 All data collected with patients enrolled in the included studies had been collected using self-  
31 administered paper-based questionnaires. The Decisional Conflict Scale (DCS) is a generic 16-  
32 item scale developed to provide an instrument to evaluate or adapt decision aids and other  
33 decision support interventions to patient needs.<sup>16</sup> When administered in the context of the  
34 included studies, a preamble described the specific decision-type addressed, and patients were  
35 asked to indicate clearly in their own words the decision they were assessing. Therefore, the  
36 DCS items were generic and the same in every case, and participants were thus expected to  
37 respond in light of this one specific decision. From the baseline data (i.e. before-and-after or  
38 randomized controlled trial studies) we extracted the following characteristics of each study: year  
39 of data collection, study type, main objective of original study, clinical setting and types of  
40 decision(s) made by patients. For each study, we assessed patient characteristics such as sex, age  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 (<45 years old,  $\geq$ 45 years old), professional status (full or part-time employment, no  
4 employment, retired), education (no postsecondary education, some postsecondary education),  
5  
6 annual household income (<CAD \$60,000,  $\geq$ \$60,000), household size (living alone, living with  
7  
8 at least one other person), marital status (married, single, separated/divorced, widowed), and  
9  
10 whether the patient had a private drug insurance plan (yes, no). We also assessed clinical  
11  
12 characteristics: whether this was the first encounter with that particular primary care provider  
13  
14 (yes, no), whether the patient was accompanied during the encounter (yes, no), whether the  
15  
16 decision was for a child (yes, no), patient preference for involvement in decision-making  
17  
18 (passive, active<sup>10 17</sup>), average annual frequency of consultations with any doctor ( $\leq$ 3, >3), self-  
19  
20 reported health status<sup>18</sup> (excellent/very good/good, or fair/poor), whether the patient received a  
21  
22 drug prescription (yes, no).  
23  
24  
25  
26  
27  
28  
29  
30  
31

### 32 *Data analysis*

33  
34 First, we computed CSDC as defined by a score of  $\geq$ 25/100 on the DCS,<sup>3 4 15 19</sup> at which point  
35  
36 decisional conflict is positively associated with decisional delay, departure from active treatment,  
37  
38 decision regret, nervousness and a higher intention to sue physicians in cases of harms from  
39  
40 treatment.<sup>3 4</sup> This is the threshold most commonly used to distinguish a harmless from a harmful  
41  
42 level of decisional conflict.<sup>3 19 20</sup> The DCS consists of 16 items, each of which is measured on a  
43  
44 5-point Likert scale (1 = strongly agree to 5 = strongly disagree, treated as a 0-4 score). The  
45  
46 mean score of all items is multiplied by 25 to give a score out of 100. Higher scores indicate  
47  
48 higher levels of decisional conflict.<sup>21</sup> The DCS shows good psychometric properties (test-retest  
49  
50 reliability coefficient: 0.81, Cronbach's alpha range: 0.78 – 0.92) and its French translation has  
51  
52 been validated.<sup>16 22-24</sup> Second, we conducted complete-subject analyses of the prevalence and risk  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 factors of CSDC individually for each dataset at the patient level. After deletion of missing data  
4 and removal of participants in experimental groups, patient characteristics were similar to those  
5  
6 of the original study populations.<sup>25 26 27 28 29</sup> In studies where clusters of patients were recruited  
7  
8 under the same clinician and/or within the same clinic, we assessed the impact of a potential  
9  
10 cluster effect at each level of analysis (clinician and/or clinic). For each dataset, we computed  
11  
12 overall prevalence of CSDC and prevalence for each category of available variables stratified by  
13  
14 sex. All results pertaining to prevalence are reported as percentages of patients with CSDC.  
15  
16 Logistic regression (backwards selection) was used to explore the independent association  
17  
18 between CSDC and potential risk factors, including interaction terms with each variable and sex.  
19  
20 All significant variables at  $\alpha \leq 0.10$  were kept in the final model. We defined statistical  
21  
22 significance at  $\alpha \leq 0.10$  because this was an exploratory study. If we found a non-negligible  
23  
24 cluster effect, we used a generalized estimation equation (PROC GENMOD) with binary logit  
25  
26 outcome. Otherwise, logistic regression was used. We calculated the receiver operating  
27  
28 characteristic to estimate the models' performance. All analyses were conducted with SAS 9.3  
29  
30 (SAS Institute Inc., Cary, NC, USA).  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

## 41 RESULTS

### 42 43 44 45 46 *Description of included studies*

47  
48  
49 We estimated the prevalence of CSDC in the context of five different studies conducted in  
50  
51 primary care. Each of these studies was designed to address different issues, and each collected  
52  
53 quite different data. However, each study group had independently identified the need to  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 measure decisional conflict using the DCS.<sup>16</sup> The following is a short description of included  
4  
5 studies.  
6  
7

8  
9  
10 The first study was a before-and-after trial conducted in Ontario to assess the impact of  
11 implementing the Ottawa Decision Support Framework (ODSF) on correspondences between  
12 patients' and physicians' decisional conflict scores. Implementation of the framework consisted  
13 of an interactive workshop, feedback, and a reminder at the point of care. Secondary objectives  
14 were to evaluate the barriers and facilitators to implementation of the ODSF in primary care  
15 practices and examine changes in physicians' intention to adopt the DSC.<sup>26</sup>  
16  
17  
18  
19  
20  
21  
22  
23

24  
25  
26 The second study evaluated decisional conflict in the context of prenatal screening for Down  
27 syndrome (GENETIC). This cross-sectional survey conducted with patients from Quebec  
28 assessed the willingness of women and their family physicians to engage in shared decision-  
29 making about prenatal Down-syndrome screening and factors that might influence this  
30 willingness.<sup>27</sup>  
31  
32  
33  
34  
35  
36  
37  
38

39  
40 The third study evaluated the impact of a training program for physicians (DECISION+).<sup>25</sup> This  
41 pilot randomized controlled trial conducted in Quebec integrated multiple educational/behavioral  
42 change components that aimed to promote shared decision-making about treatment options and  
43 specifically about the use of antibiotics for acute respiratory infections.<sup>25</sup>  
44  
45  
46  
47  
48  
49  
50

51  
52 The goal of the fourth study was to assess the psychometric properties of dyadic measures for  
53 shared decision-making research. The study used a shared decision-making model (EXACKTE2)  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 to explore how patients and clinicians influence one another. This cross-sectional study  
4  
5 conducted in 17 primary care clinics in Ontario and Quebec explored the mutual influence  
6  
7 between patients and physicians during consultations.<sup>28</sup>  
8  
9

10  
11  
12 The last study used data gathered during a pilot study<sup>25</sup> to establish the feasibility of conducting  
13  
14 the DECISION+ training program on a larger scale. The program was improved and renamed  
15  
16 DECISION+2<sup>29</sup> before the definitive trial. This randomized controlled trial conducted in Quebec  
17  
18 assessed the impact of DECISION+2 on antibiotics use for acute respiratory infections.  
19  
20  
21

22  
23  
24 Table 1 presents the characteristics of the included studies and their related datasets alongside the  
25  
26 available independent variables.<sup>25-29</sup> All datasets were from projects conducted between 2003  
27  
28 and 2010. Three were conducted in the province of Quebec, one was conducted in Ontario and  
29  
30 one was conducted jointly by teams from Ontario and Quebec.<sup>28</sup> Of the five datasets available,  
31  
32 two were clustered randomized trials (DECISION+<sup>25</sup>, DECISION+2<sup>29</sup>), two were cross-sectional  
33  
34 surveys (GENETIC<sup>27</sup>, EXACKTE2<sup>28</sup>) and one was a before-and-after trial (iODSF<sup>26</sup>). Decisions  
35  
36 were about undergoing a prenatal Down syndrome genetic screening test (GENETIC<sup>27</sup>), taking  
37  
38 antibiotics to treat acute respiratory infections (DECISION+<sup>25</sup>, DECISION+2<sup>29</sup>) and various  
39  
40 other primary care decisions (iODSF<sup>26</sup>, EXACKTE2<sup>28</sup>). Altogether, data from 1,338 primary  
41  
42 care patients were analyzed. Patients were aged between 15 and 83 years old and 69% were  
43  
44 female.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

**Table 1:** Characteristics of datasets

Characteristics	Dataset				
	iODSF <sup>26</sup>	GENETIC <sup>27</sup>	DECISION+ <sup>25</sup>	EXACKTE2 <sup>28</sup>	DECISION+2 <sup>29</sup>
<b>Year of data collection</b>	2003	2007	2007	2009	2010
<b>Study type</b>	Before and after trial	Cross-sectional survey	Cluster randomized trial	Cross-sectional survey	Cluster randomized trial
<b>Main objective of study</b>	To assess the impact of implementing the Ottawa Decision Support Framework on correspondences between patients' and physicians' decisional conflict scores.	To assess the willingness of women and their family physicians to engage in shared decision making about prenatal Down-syndrome screening and the factors that might influence this willingness.	To develop, adapt and validate a shared decision-making training program and estimate its impact on the decision of family physicians and their patients about whether to use antibiotics for ARIs.	To assess the psychometric properties of dyadic measures for shared decision-making research.	To evaluate the effect of a shared decision-making training program on decisions of family physicians and their patients about whether to use antibiotics for ARIs.
<b>Clinical setting</b>	5 FPTUs in the Quebec City area	3 FPTUs in the Quebec City area	4 family medicine groups in the Quebec City area	17 primary care clinics in the Quebec City area and in Ontario	9 FPTUs in the province of Quebec
<b>Type of decision</b>	Various other primary care decisions	To do a prenatal test or not	To take antibiotics or not for treating ARIs	Various other primary care decisions	To take antibiotics or not for treating ARIs
<b>Total participants (N)</b>	370	130	225	198	415
<b>Women; n (%)</b>	234 (63)	130 (100)	154 (68)	131 (66)	277 (67)
<b>Aged ≥ 45 years old; n(%)</b>	209 (56)	0 (0)	60 (27)	117 (59)	164 (40)
<b>Living by themselves; n(%)</b>	119 (32)	1 (1)	39 (17)	42 (21)	74 (18)
<b>Professional status; n(%)</b>					
- Employed full- or part-time	185 (50)	105 (81)	176 (78)	109 (55)	318 (77)
- Unemployed	69 (19)	25 (19)	36 (16)	30 (15)	65 (16)
- Retired	116 (31)	0 (0)	13 (6)	59 (30)	32 (8)
<b>Household income ≥ \$ 60,000; n (%)</b>	97 (26)	62 (48)	87 (39)	24 (12)	194 (47)
<b>Available variables</b>	Age, sex, employment status, education, annual income, household size, first encounter with that doctor	Age, sex, employment status, education, annual income, household size	Age, sex, employment status, education, annual income, household size, first encounter with that doctor, patient preference for involvement in decision-making, self-reported health status, whether making a decision for a child, whether patient receives a prescription, whether patient has a private drug insurance plan	Age, sex, employment status, education, annual income, household size, marital status, average annual frequency of physician visits, first encounter with that doctor, patient is alone or accompanied	Age, sex, employment status, education, annual income, household size, first encounter with that doctor, patient preference for involvement in decision making, self-reported health status, whether making a decision for a child, whether patient receives a prescription, whether patient has a private drug insurance plan

FPTU: Family practice teaching unit; ARIs: Acute respiratory infections

1  
2  
3 *Prevalence of clinically significant decisional conflict*  
4  
5  
6  
7

8 Table 2 shows the prevalence as a percentage of included participants with CSDC across all five  
9 datasets stratified by sex for available variables, since gender was found to be a modifying factor  
10 for at least one variable in all four datasets that included men. Prevalence was between 10.3%  
11 (iODSF<sup>26</sup>) (95% confidence intervals [CI]: 7.2 – 13.4) and 31.1% (DECISION+2<sup>29</sup>) (95%CI:  
12 26.6 – 35.6). CSDC was consistently more prevalent in males (4/4 studies), people aged 45 or  
13 older (4/4 studies), people living alone (4/5 studies), retirees (4/4 studies), people preferring  
14 active participation in decision making (2/2 studies), people reporting poor health status (2/2  
15 studies), people making the decision for themselves as opposed to for their children (2/2 studies),  
16 and people who did not have a private drug insurance plan (2/2 studies).  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 2:** Prevalence\* of clinically significant decisional conflict according to datasets and sex

	iODSF <sup>26</sup>			GENETIC <sup>27</sup>	DECISION+ <sup>25</sup>			EXACKTE2 <sup>28</sup>			DECISION+2 <sup>29</sup>		
	F	M	All	All†	F	M	All	F	M	All	F	M	All
<b>Total participants (N)</b>	234	136	370	130	154	71	225	131	67	198	277	138	415
<b>Overall prevalence (95% confidence interval)</b>	7.7 (4.3; 11.1)	14.7 (8.7; 20.7)	10.3 (7.2; 13.4)	16.9 (10.4; 23.5)	17.5 (11.5; 23.6)	31.0 (20.0; 42.0)	21.8 (16.3; 27.2)	15.3 (9.0; 21.5)	28.4 (17.3; 39.4)	19.7 (14.1; 25.3)	28.5 (23.2; 33.9)	36.2 (28.1; 44.4)	31.1 (26.6; 35.6)
<b>Adjusted Chronbach Alpha rates (DCS)</b>	0.85			0.93	0.91			0.95			0.93		
<b>Sociodemographic characteristics</b>													
<b>Age</b>													
< 45 years old	6.1	13.0	8.1	16.9	11.5	27.0	16.4	10.9	17.7	12.4	26.0	29.2	26.9
≥ 45 years old	9.2	15.6	12.0	N/A	34.2	42.1	36.7	19.4	32.0	24.8	36.2	50.0	41.5
<b>Professional status</b>													
Full- or part-time employment	9.3	14.9	11.4	18.1	17.7	28.1	21.0	10.8	25.7	15.6	27.6	37.0	30.8
No employment	6.0	0.0	4.4	12.0	11.5	50.0	22.2	18.2	25.0	20.0	29.8	27.8	29.2
Retired	6.1	20.0	12.1	N/A	33.3	25.0	30.8	22.9	33.3	27.1	35.0	41.7	37.5
<b>Education</b>													
No postsecondary education	5.9	14.4	9.1	9.8	16.0	34.7	23.4	26.0	21.4	24.4	26.3	33.3	28.9
At least some postsecondary education	11.1	15.2	12.6	21.5	19.0	22.7	19.8	8.7	33.3	16.7	29.4	37.8	32.1
<b>Annual household income</b>													
< \$60,000	5.1	13.3	8.1	17.7	14.1	41.3	23.2	15.0	24.1	17.8	32.3	30.3	31.7
≥ \$60,000	15.3	18.4	16.5	16.1	22.6	12.0	19.5	18.2	46.1	33.3	23.8	41.7	30.4
<b>Household size</b>													
Living alone	9.2	23.3	14.3	0.0	31.8	47.1	38.5	25.0	36.4	31.0	42.9	40.0	41.9
Living with ≥ 1 other person	7.0	10.8	8.4	17.1	15.2	25.9	18.3	13.5	24.4	16.7	25.4	35.4	28.7
<b>Marital status</b>													
Married								9.3	25.0	13.9			
Single								25.0	27.8	26.2			
Separated /divorced								33.3	44.4	38.1			
Widowed								22.2	25.0	23.1			
<b>Private drug insurance plan</b>													
Yes					17.5	26.0	20.1				26.3	35.6	29.4
No					17.5	42.9	26.2				34.2	37.8	35.3

F = Female; M = Male; N/A = Not applicable; \* Prevalence of Clinically Significant Decisional Conflict was defined as a score ≥ 25/100 on the Decisional Conflict Scale (DCS)<sup>15</sup>; † In the GENETIC study, all participants were female.



**Table 2:** Prevalence\* of clinically significant decisional conflict according to datasets and sex (continuation)

Clinical characteristics	iODSF <sup>26</sup>			GENETIC <sup>27</sup>	DECISION+ <sup>25</sup>			EXACKTE2 <sup>28</sup>			DECISION+2 <sup>29</sup>		
	F	M	All	All†	F	M	All	F	M	All	F	M	All
<b>First encounter with that particular doctor</b>													
Yes	8.5	18.6	12.8		12.5	31.8	17.4	17.8	36.4	23.5	32.6	25.9	30.1
No	7.4	12.9	9.3		21.1	31.6	24.5	15.7	24.4	18.4	27.7	38.7	31.3
<b>Patient accompanied during encounter</b>													
Yes								11.1	33.3	18.5			
No								15.9	27.6	19.9			
<b>Decision for a child</b>													
Yes					10.0	31.2	15.2				22.9	30.0	25.0
No					21.2	30.9	24.5				30.4	38.0	33.0
<b>Patient preference for involvement</b>													
Passive					15.2	30.4	20.3				27.8	26.7	27.3
Active					21.0	32.0	24.1				28.6	37.4	31.4
<b>Average annual frequency of physician visits</b>													
≤ 3 average physician visits per year								9.9	39.4	19.2			
> 3 average physician visits per year								21.7	17.7	20.2			
<b>Self-reported health status</b>													
Excellent, very good, good					16.7	27.4	19.9				27.5	32.8	29.2
Fair, poor					30.0	55.6	42.1				40.9	69.2	51.4
<b>Patient received a prescription</b>													
Yes					16.4	32.8	21.7				29.5	34.6	31.1
No					23.1	20.0	22.2				24.5	42.9	30.9

F = Female; M = Male; N/A: Not applicable; \* Prevalence of Clinically Significant Decisional Conflict was defined as a score  $\geq 25/100$  on the Decisional Conflict Scale<sup>15</sup>; †In GENETIC study, all participants were female.

*Risk factors of clinically significant decisional conflict*

The impact of cluster effect at the clinician level was found to be negligible in all datasets. However, we found a cluster effect at the clinic level in three projects (iODSF<sup>26</sup>, DECISION+<sup>25</sup>, DECISION+2<sup>29</sup>). Table 3 presents the multivariable regression analysis of the association between CSDC and its potential independent risk factors. Sex was found to be a modifying factor for at least one variable in all datasets (except GENETIC<sup>27</sup>, as all participants were women) and an independent risk factor in one (EXACKTE2<sup>28</sup>). We tested the interaction between the patient's gender and the first visit with a physician but found that it was not significant (data not shown). Living alone was positively associated with CSDC in three out of four datasets (iODSF<sup>26</sup>, DECISION+<sup>25</sup>, DECISION+2<sup>29</sup>). Being aged 45 or older was also positively associated with CSDC in three out of four datasets (DECISION+<sup>25</sup>, EXACKTE2<sup>28</sup>, DECISION+2<sup>29</sup>) and there was a significant interaction with sex in one dataset (iODSF<sup>26</sup>). An annual income above or equal to CAD \$60,000 was positively associated with CSDC in two of the five datasets (iODSF<sup>26</sup>, EXACKTE2<sup>28</sup>) and we observed an interaction term with sex in one dataset (DECISION+<sup>25</sup>). Other study variables were not significantly associated with CSDC in more than one study.

**Table 3:** Association between clinically significant decisional conflict and potential risk factors according to dataset

Potential risk factors	Dataset									
	iODSF <sup>26</sup>		GENETIC <sup>27</sup>		DECISION+ <sup>25</sup>		EXACKTE2 <sup>28</sup>		DECISION+2 <sup>29</sup>	
	$\beta \pm SE$	<i>p</i> -value	$\beta \pm SE$	<i>p</i> -value	$\beta \pm SE$	<i>p</i> -value	$\beta \pm SE$	<i>p</i> -value	$\beta \pm SE$	<i>p</i> -value
Sex (being male)	-0.54 ± 0.58	0.36	n = 0		-0.35 ± 0.56	0.54	1.45 ± 0.56	<b>0.01</b>	0.39 ± 0.25	0.11
Postsecondary education	-		0.93 ± 0.54	0.08	-		-0.79 ± 0.43	0.07	-	
Age (≥45)	0.66 ± 0.57	0.25	n = 0		1.02 ± 0.24	<b>&lt; 0.0001</b>	0.57 ± 0.45	0.09	0.61 ± 0.18	<b>&lt; 0.001</b>
Age (≥45) x sex	1.40 ± 0.39	<b>&lt; 0.001</b>	N/A		-		-		-	
Living alone	1.01 ± 0.23	<b>&lt; 0.0001</b>	n = 1		0.81 ± 0.25	<b>&lt; 0.01</b>	-		0.40 ± 0.17	0.02
Making the decision for a child (vs. for self)	N/A		N/A		-0.73 ± 0.39	0.06	N/A		-	
Making the decision for a child (vs. for self) x sex	N/A		N/A		1.20 ± 0.19	<b>&lt; 0.0001</b>	N/A		-	
Having received a prescription	N/A		N/A		-0.66 ± 0.25	<b>&lt; 0.01</b>	N/A		-	
Having received a prescription x sex	N/A		N/A		1.93 ± 0.10	<b>&lt; 0.0001</b>	N/A		-	
Annual family income ≥ \$60K	1.16 ± 0.13	<b>&lt; 0.0001</b>	-		1.19 ± 0.24	<b>&lt; 0.0001</b>	1.11 ± 0.56	<b>0.05</b>	-	
Annual family income ≥ \$60K x sex	-		N/A		-2.54 ± 0.69	<b>&lt; 0.001</b>	-		-	
Being unemployed	-0.89 ± 0.31	<b>&lt; 0.01</b>	-		-		-		0.15 ± 0.42	0.71
Being unemployed x sex	-		N/A		-		-		-0.98 ± 0.22	<b>&lt; 0.0001</b>
Retirement	-0.86 ± 0.44	<b>0.05</b>	n = 0		-		-		-0.34 ± 0.49	0.49
Being retired x sex	1.83 ± 0.69	<b>&lt; 0.01</b>	N/A		-		-		0.16 ± 0.76	0.83
Being single (vs. being married)	N/A		N/A		N/A		1.16 ± 0.54	<b>0.03</b>	N/A	
Being separated or divorced (vs. being married)	N/A		N/A		N/A		0.22 ± 0.74	0.76	N/A	
Self-reported health status “Excellent”, “Very good” or “good”	N/A		N/A		-		N/A		-0.95 ± 0.28	<b>&lt; 0.001</b>
Consulting a physician > 3 times a year	N/A		N/A		N/A		0.39 ± 0.55	0.48	N/A	
Consulting a physician > 3 times a year x sex	N/A		N/A		N/A		-1.92 ± 0.81	<b>0.02</b>	N/A	
<b>ROC</b>	<b>0.73</b>		<b>0.60</b>		<b>0.76</b>		<b>0.75</b>		<b>0.62</b>	

$\beta$  = Regression coefficient; SE = Standard error; N/A = Not available; ROC = Receiver operating characteristic

## DISCUSSION

Using data on a total of 1,338 patients from combination of five studies conducted in primary care contexts in two Canadian provinces, Quebec and Ontario, we observed that the prevalence of CSDC in patients, defined as a score of  $\geq 25/100$  on the DCS, was substantial and varied between 10% and 31%. Populations at risk of CSDC included males, people living alone and people aged 45 years or older. To the best of our knowledge, this is the first account of the prevalence of CSDC as reported in studies conducted exclusively in primary care and with this many unique clinical encounters. None of the earlier studies measuring CSDC in a primary care clinical context focused on a decision dealt with entirely at the primary care level.<sup>30-33</sup> Our results lead us to make four main observations.

First, our results contradict a common belief that primary care only deals with mundane types of decisions that involve no perception of risk, loss, regret, or challenges to personal life values, and that primary care decisions therefore involve no personal uncertainty. Clearly, this is not how some patients enrolled in these five studies saw the issues they were confronting. Given the harmful downstream effects of unresolved CSDC, our results suggest that a significant number of primary care patients would benefit greatly from patient decision aids,<sup>12</sup> decision coaching<sup>34</sup> or from their healthcare providers being trained in shared decision-making. These clinical approaches are known to be effective in resolving CSDC.<sup>35</sup>

Second, we observed a higher prevalence of CSDC in men than in women in all four datasets that included men and women. Moreover, sex was found to be an independent risk factor in one

1  
2  
3 dataset and significantly interacted with at least one variable in all datasets. This may be  
4 explained by the fact that more women than men report having a regular family doctor<sup>36</sup> and  
5 consulting primary care providers over their lifetime.<sup>37</sup> Women tend to consult healthcare  
6 providers more frequently due to their gynecological and obstetrical needs and also because they  
7 are often involved in health-related decision making for other family members.<sup>37 38</sup> Furthermore,  
8 physicians are known to discuss therapeutic and preventive interventions more often with women  
9 than with men.<sup>39</sup> Together, more visits to physicians and more discussion with them may  
10 contribute to a higher sense of self-efficacy among women about engaging in decision-making.<sup>40</sup>  
11 This in turn could reduce CSDC in women.<sup>40</sup> Since sex was not an independent risk factor across  
12 all studies, it would be erroneous to conclude that men are systematically more at risk of CSDC  
13 than women. As in earlier studies on the impact of sex on outcomes, our results highlight a  
14 significant effect of sex on CSDC and suggest that primary care providers should tailor their  
15 decision-making approach to the patient's sex.<sup>41</sup>

16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37 Third, people reporting living alone showed a consistently higher prevalence of CSDC than  
38 people reporting living with at least one other person. This is congruent with the theory  
39 underlying the DCS.<sup>16</sup> The higher prevalence of CSDC in people reporting living alone could be  
40 due to a lack of social support when they face health-related decisions, one of the key  
41 contributors to CDSC.<sup>5</sup> During the clinical encounter, primary care providers should explore the  
42 patient's social support systems, i.e. whether he/she can 1) check other people's opinions, 2)  
43 focus on those whose opinions matter most (physician, family, and friends) and 3) handle diverse  
44 sources of pressure.<sup>42</sup> Such support-clarification exercises help patients understand other  
45 perspectives and gather opinions about what other people would do if they were in the same  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 situation. Our results suggest that lack of support for people living alone may aggravate CSDC in  
4 primary care patients. Although the contribution of family members is increasingly recognized as  
5 an important source of social support for patients facing health decisions,<sup>43</sup> the literature has still  
6 not adequately addressed its full impact on decision-making.<sup>44</sup> Primary care providers should pay  
7 closer attention to their patients living alone in their efforts to detect CSDC during the decision-  
8 making process.  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19

20 Lastly, patients aged 45 or older showed a higher prevalence of CSDC in all relevant datasets. As  
21 older adults tend to seek less information when making a decision, defer the decision more often,  
22 and are generally more risk avoidant than young adults, they may be more at risk of CSDC.<sup>45</sup> In  
23 addition, an enduring myth is that older and more vulnerable patients are less interested in  
24 participating in decision-making with their healthcare providers than are less vulnerable  
25 patients.<sup>46</sup> Any and all of these reasons may contribute to the higher prevalence of CSDC  
26 observed in populations aged 45 years or older and should inform clinicians and researchers of  
27 the urgent need to foster the participation of older patients in decision-making with the  
28 appropriate strategies.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

43 Our study has some limitations. First, measuring CSDC was not the primary objective of any of  
44 the selected studies. Also, potentially relevant variables such as marital status and self-reported  
45 health status were missing in some datasets, and therefore we could not draw conclusions  
46 relating to these variables. Furthermore, all studies were weighted equally, as a meta-analysis  
47 was not judged appropriate given the heterogeneity of the data sets (type of decision, study  
48 design, available variables). Nevertheless, the similar nature of the questionnaires in each study  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 enabled us to compare associations in datasets independently from one another and thus assure  
4 external validity of the results.<sup>47</sup> We also acknowledge that there might be a selection bias in the  
5 included studies and thus our results will need to be reproduced in future studies. Also, there  
6 might be bias within the studies resulting from patients who willingly participated in the study  
7 and regarding the study design. However, we performed multivariate analyses to adjust for  
8 confounding factors. Finally, we acknowledge that we cannot infer that our results are  
9 generalizable to the wider population as we drew upon secondary analysis of existing datasets of  
10 studies conducted in specific primary care clinical contexts in two provinces in Canada. Further  
11 studies with appropriate survey methods and sampling frames could depict a more accurate  
12 portrait of CSDC in other primary care clinical contexts, and explore how much the prevalence  
13 varies according to decision-type.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

## 32 CONCLUSION

33  
34  
35  
36 We observed that the prevalence of CSDC in studies on decision-making conducted in primary  
37 care contexts in two Canadian provinces, Quebec and Ontario, ranged from 10% to 31%. This  
38 prevalence varied depending on the type of decision and was higher in males, in people living  
39 alone, and in people aged 45 or older. Although we cannot generalize our results to the wider  
40 population, they should alert primary care providers to patients who may be at higher risk of  
41 CSDC. Training health professionals to identify CDSC in patients and ensuring that effective  
42 decision support interventions such as patient decision aids are implemented at the point of care  
43 should be encouraged to resolve CDSC.<sup>12 48</sup>  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

1. Carpenito-Moyet L. Individual Nursing Diagnoses: Decisional Conflict. In: Carpenito-Moyet L, ed. *Nursing Diagnosis: Application to Clinical Practice*. 13 ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2010.
2. Janis I, Mann L. *Decision making: a psychological analysis of conflict, choice, and commitment*. New York: Free Press, 1977.
3. Knops AM, Goossens A, Ubbink DT, et al. Interpreting patient decisional conflict scores: behavior and emotions in decisions about treatment. *Med Decis Making* 2013;33(1):78-84.
4. Sun Q. Predicting Downstream Effects of High Decisional Conflict: Meta-analyses of the Decisional Conflict Scale. University of Ottawa, 2004.
5. O'Connor AM, Tugwell P, Wells GA, et al. A decision aid for women considering hormone therapy after menopause: decision support framework and evaluation. *Patient Educ Couns* 1998;33(3):267-79.
6. Starfield B, Shi L, Macinko J. Contribution of primary care to health systems and health. *Milbank Q* 2005;83(3):457-502.
7. Hsu C, Phillips WR, Sherman KJ, et al. Healing in primary care: a vision shared by patients, physicians, nurses, and clinical staff. *Ann Fam Med* 2008;6(4):307-14.
8. Orasanu J, Connolly T. The reinvention of decision making. In: Klein G, Orasanu J, Calderwood R, et al., eds. *Decision making in action: models and methods*. Norwood, NJ: Ablex Publishing Corporation, 1993.
9. Braddock CH, 3rd. Supporting shared decision making when clinical evidence is low. *Medical Care Res Rev* 2013;70(1 Suppl):129S-40S.
10. Legare F, Guerrier M, Nadeau C, et al. Impact of DECISION + 2 on patient and physician assessment of shared decision making implementation in the context of antibiotics use for acute respiratory infections. *Implement Sci* 2013;8:144.
11. Holzel LP, Kriston L, Harter M. Patient preference for involvement, experienced involvement, decisional conflict, and satisfaction with physician: a structural equation model test. *BMC Health Serv Res* 2013;13:231.
12. Stacey D, Legare F, Col NF, et al. Decision aids for people facing health treatment or screening decisions. *The Cochrane Database Syst Rev* 2014;1:CD001431.
13. Canada research chair in implementation of shared decision making in primary care. Practice-Based Research Network: Laboratory for the Implementation of Shared Decision Making in Primary Care. Secondary Canada research chair in implementation of shared decision making in primary care. Practice-Based Research Network: Laboratory for the Implementation of Shared Decision Making in Primary Care. 2014. <http://www.decision.chaire.fmed.ulaval.ca/en/pbrn/>.
14. Muldoon LK, Hogg WE, Levitt M. Primary care (PC) and primary health care (PHC). What is the difference? *Canadian journal of public health = Revue canadienne de sante publique* 2006;97(5):409-11.



15. O'Connor A. User Manual - Decisional Conflict Scale. Secondary User Manual - Decisional Conflict Scale 2010 1993.  
[http://decisionaid.ohri.ca/docs/develop/User\\_Manuals/UM\\_Decisional\\_Conflict.pdf](http://decisionaid.ohri.ca/docs/develop/User_Manuals/UM_Decisional_Conflict.pdf).
16. O'Connor AM. Validation of a decisional conflict scale. *Med Decis Making* 1995;**15**(1):25-30.
17. Strull WM, Lo B, Charles G. Do patients want to participate in medical decision making? *JAMA* 1984;**252**(21):2990-4.
18. Ware J, Jr., Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. *Medical care* 1996;**34**(3):220-33.
19. Prevalence of Clinically Significant Decisional Conflict in Primary Care: A Scoping Review. International Shared Decision-making Conference 2013 16-19 Jun; Lima, Peru.
20. Ferron Parayre A, Labrecque M, Rousseau M, et al. Validation of SURE, a four-item clinical checklist for detecting decisional conflict in patients. *Med Decis Making* 2014;**34**(1):4-62.
21. Le Collège des médecins de famille du Canada. La pratique de la médecine familiale: Le Centre de médecine de famille, 2011.
22. Kryworuchko J, Stacey D, Bennett C, et al. Appraisal of primary outcome measures used in trials of patient decision support. *Patient Educ Couns* 2008;**73**(3):497-503.
23. Mancini J, Santin G, Chabal F, et al. Cross-cultural validation of the Decisional Conflict Scale in a sample of French patients. *Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation* 2006;**15**(6):1063-8.
24. Joosten EA, DeFuentes-Merillas L, de Weert GH, et al. Systematic review of the effects of shared decision-making on patient satisfaction, treatment adherence and health status. *Psychother Psychosom* 2008;**77**(4):219-26.
25. Legare F, Labrecque M, LeBlanc A, et al. Training family physicians in shared decision making for the use of antibiotics for acute respiratory infections: a pilot clustered randomized controlled trial. *Health Expect* 2011;**14** Suppl 1:96-110.
26. Legare F, O'Connor AM, Graham ID, et al. Impact of the Ottawa Decision Support Framework on the agreement and the difference between patients' and physicians' decisional conflict. *Med Decis Making* 2006;**26**(4):373-90.
27. Legare F, St-Jacques S, Gagnon S, et al. Prenatal screening for Down syndrome: a survey of willingness in women and family physicians to engage in shared decision-making. *Prenat Diagn* 2011;**31**(4):319-26.
28. Legare F, Turcotte S, Robitaille H, et al. Some but not all dyadic measures in shared decision making research have satisfactory psychometric properties. *J Clin Epidemiol* 2012;**65**(12):1310-20.
29. Legare F, Labrecque M, Cauchon M, et al. Training family physicians in shared decision-making to reduce the overuse of antibiotics in acute respiratory infections: a cluster randomized trial. *CMAJ* 2012;**184**(13):E726-34.
30. Arimori N. Randomized controlled trial of decision aids for women considering prenatal testing: The effect of the Ottawa Personal Decision Guide on decisional conflict. *Japan Journal of Nursing Science* 2006;**3**(2):119-30.
31. Kremer H, Ironson G, Schneiderman N, et al. "It's my body": does patient involvement in decision making reduce decisional conflict? *Med Decis Making* 2007;**27**(5):522-32.
32. McCaffery KJ, Irwig L, Chan SF, et al. HPV testing versus repeat Pap testing for the management of a minor abnormal Pap smear: evaluation of a decision aid to support informed choice. *Patient Educ Couns* 2008;**73**(3):473-9, 81.

- 1
- 2
- 3
- 4 33. Montgomery AA, Emmett CL, Fahey T, et al. Two decision aids for mode of delivery among
- 5 women with previous caesarean section: randomised controlled trial. *BMJ*
- 6 2007;334(7607):1305.
- 7 34. O'Connor AM, Stacey D, Legare F. Coaching to support patients in making decisions. *BMJ*
- 8 2008;336(7638):228-9.
- 9 35. Legare F, Stacey D, Turcotte S, et al. Interventions for improving the adoption of shared
- 10 decision making by healthcare professionals. *The Cochrane Database Syst Rev*
- 11 2014;9:CD006732.
- 12 36. Dubé-linteau A, Pineault R, Levesque J-F, et al. Enquête québécoise sur l'expérience de
- 13 soins 2010-2011. *Le médecin de famille et l'endroit habituel de soins : regard sur*
- 14 *l'expérience vécue par les Québécois*. Québec: Institut de la statistique du Québec,
- 15 2013:73.
- 16 37. Wang Y, Hunt K, Nazareth I, et al. Do men consult less than women? An analysis of
- 17 routinely collected UK general practice data. *BMJ open* 2013;3(8):e003320.
- 18 38. Scaife B, Gill P, Heywood P, et al. Socio-economic characteristics of adult frequent attenders
- 19 in general practice: secondary analysis of data. *Fam Pract* 2000;17(4):298-304.
- 20 39. Bertakis KD, Azari R. Patient gender and physician practice style. *J Womens Health*
- 21 2007;16(6):859-68.
- 22 40. Joseph-Williams N, Elwyn G, Edwards A. Knowledge is not power for patients: a systematic
- 23 review and thematic synthesis of patient-reported barriers and facilitators to shared
- 24 decision making. *Patient Educ Couns* 2014;94(3):291-309.
- 25 41. Bertakis KD. The influence of gender on the doctor-patient interaction. *Patient Educ Couns*
- 26 2009;76(3):356-60.
- 27 42. O'Connor A, Joosten M. Decisional Conflict: Supporting People Experiencing Uncertainty
- 28 about Options Affecting their Health. *Secondary Decisional Conflict: Supporting People*
- 29 *Experiencing Uncertainty about Options Affecting their Health* 2007.
- 30 [http://homeless.ehclients.com/images/uploads/W-2\\_Ottawa\\_Decision\\_Making\\_tool--](http://homeless.ehclients.com/images/uploads/W-2_Ottawa_Decision_Making_tool--Reading-1.pdf)
- 31 [Reading-1.pdf](http://homeless.ehclients.com/images/uploads/W-2_Ottawa_Decision_Making_tool--Reading-1.pdf).
- 32 43. Clayman ML, Morris MA. Patients in context: recognizing the companion as part of a
- 33 patient-centered team. *Patient Educ Couns* 2013;91(1):1-2.
- 34 44. Siminoff LA. Incorporating patient and family preferences into evidence-based medicine.
- 35 *BMC medical informatics and decision making* 2013;13 Suppl 3:S6.
- 36 45. Mather M. A Review of Decision-Making Processes: Weighing the Risks and Benefits of
- 37 Aging. In: LL C, CR H, eds. *When I'm 64*. Washington, DC: National Academies Press
- 38 (US), 2006.
- 39 46. Legare F, Thompson-Leduc P. Twelve myths about shared decision making. *Patient Educ*
- 40 *Couns* 2014;96(3):281-6.
- 41 47. Ioannidis JP. Why most published research findings are false. *PLoS medicine* 2005;2(8):e124.
- 42 48. Towle A, Godolphin W. Framework for teaching and learning informed shared decision
- 43 making. *BMJ* 1999;319(7212):766-71.
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

## PRISMA Checklist

### PREVALENCE OF CLINICALLY SIGNIFICANT DECISIONAL CONFLICT: AN ANALYSIS OF FIVE STUDIES ON DECISION MAKING IN PRIMARY CARE

Philippe Thompson-Leduc, MSc  
Stéphane Turcotte, MSc  
Centre Hospitalier Universitaire de Québec Research Centre, Quebec City, Canada

Michel Labrecque, MD PhD CCMF FCMF  
France Légaré, MD PhD CCMF FCMF  
Titular Professors  
Department of Family Medicine and Emergency Medicine, Faculty of Medicine, Laval  
University, Quebec City, Canada  
Centre Hospitalier Universitaire de Québec Research Centre, Quebec City, Canada

Corresponding Author :  
France Légaré MD PhD CCMF FCMF  
Address : Centre Hospitalier Universitaire de Québec Research Centre, Quebec City,  
Canada, Hôpital St-François d'Assise, 10 rue Espinay, Quebec City, Quebec, Canada  
E-mail : [france.legare@mfa.ulaval.ca](mailto:france.legare@mfa.ulaval.ca)  
Phone : 418-525-4437  
Fax : 418-525-4194

Criteria		Page	Brief description of how the criteria were handled in the manuscript
<b>TITLE</b>			
1	Identify the report as a systematic review, meta-analysis, or both.	p. 1	PREVALENCE OF CLINICALLY SIGNIFICANT DECISIONAL CONFLICT: AN ANALYSIS OF FIVE STUDIES ON DECISION MAKING IN PRIMARY CARE
<b>ABSTRACT</b>			
2	Provide a structured summary including, as applicable: Background (research question and main objectives); Methods (data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods); Results (number and type of studies and participants, main	pp. 4-5	<b>Objectives:</b> Unresolved clinically significant decisional conflict (CSDC) in patients following a consultation with health professionals is often the result of inadequate patient involvement in decision-making and may result in poor outcomes. We sought to identify the prevalence of CSDC in studies on decision-making in primary care and to explore its risk factors.

<p>outcomes with CI); Discussion (strengths and limitations of the evidence, general interpretation and important implications) Other (report primary funding source, registration number)</p>		<p><b>Setting:</b> We performed a secondary analysis of existing datasets from studies conducted in Primary Care Practice-Based Research Networks in Quebec and Ontario, Canada.</p> <p><b>Participants:</b> Eligible studies included a patient-reported measure on the 16-item Decisional Conflict Scale (DCS) following a decision made with a healthcare professional with no study design restriction.</p> <p><b>Primary and secondary outcome measures:</b> CSDC was defined as a score <math>\geq 25/100</math> on the DCS. The prevalence of CSDC was stratified by sex; and patient-level logistic regression analysis was performed to explore its potential risk factors. Datasets of studies were analyzed individually and qualitatively compared.</p> <p><b>Results:</b> Five projects conducted between 2003 and 2010 were included. They covered a range of decisions: prenatal genetic screening, antibiotics for acute respiratory infections and miscellaneous. Altogether, the five projects gathered data from encounters with a total of 1,338 primary care patients (69% female; range of age: 15 to 83). The prevalence of CSDC in patients varied across studies and ranged from 10.3% (95% confidence interval: 7.2% – 13.4%) to 31.1% (95% confidence interval: 26.6% – 35.6%). Across the five studies, risk factors of CSDC included being male, living alone, and being 45 or older.</p> <p><b>Conclusions:</b> Prevalence of CSDC in patients who had enrolled in studies conducted in primary care contexts was substantial and appeared to vary according to the type of decision as well as to patient characteristics such as sex, living arrangement and age. Patients presenting risk factors of CSDC should be offered tools to increase their involvement in decision-making.</p>
<b>INTRODUCTION</b>		

3	<i>Rationale</i> : describe the rationale for the review in the context of what is already known.	p. 7	When facing health-related decisions and presented with multiple options, patients are subject to uncertainty about what to choose. This uncertainty is known as decisional conflict. Decisional conflict is an intra-personal psychological construct that is felt by individuals when facing decisions that involve risk, loss, regret, or challenges to personal life values. <sup>1 2</sup> In lay terms, decisional conflict reflects the level of comfort that an individual faces in making a decision. In some patients it may translate into clinically significant decisional conflict (CSDC), at which point decisional conflict is positively associated with decisional delay, departure from active treatment, decision regret, nervousness and a higher intention to sue physicians in cases of harms from treatment. <sup>3 4</sup> Thus it is essential to identify patients experiencing CSDC, as there are several modifiable deficits that lead to CSDC, including 1) inadequate knowledge of options; 2) unclear values regarding harms and benefits of options; and 3) inadequate support or resources for decision making. These may all be addressed with effective decision support. <sup>5</sup>
4	<i>Objectives</i> : provide an explicit statement of questions being addressed with reference to participants, intervention, comparisons, outcomes, and study design (PICOS)	p. 8	“Analyzing (S) and comparing (C) the outcomes (O) of decision-making studies (I) among primary care patients (P) could thus have a beneficial impact on the quality of care for a large number of individuals. We sought to identify the prevalence of CSDC in studies conducted in primary care contexts and to explore its risk factors ( <i>Objective</i> ).”
<b>METHODS</b>			Data extracted from each of the studies were relevant to the population characteristics, study design, exposure, outcome, and possible effect modifiers of the association.
5	<i>Protocol and registration</i>	N/A	There was no registered protocol, but the first author performed a protocol for this study in his masters degree.
6	<i>Eligibility criteria</i> (studies characteristics, the rationale for criteria should be stated)	pp. 8-9	Studies were included if 1) they were set entirely in primary care (defined as the patient’s point of entry into the healthcare system, most often consulting a family physician <sup>14</sup> ); 2) they assessed patient-

			reported decisional conflict using the French or English version of the 16-item Decisional Conflict Scale (DCS) (i.e. studies conducted after the development of the DCS in 1993); <sup>15</sup> and 3) DCS scores were collected from patients following a clinical encounter with a primary care provider. There was no study design restriction. Studies were excluded if data had been gathered in a specialized clinic, if participants were recruited from the public (through newspaper ads, for instance), or if data collected with individuals did not relate to a clinical encounter with a primary care provider. For experimental studies, only patients from control or baseline groups were considered for analysis.
7	<i>Information sources</i> (details of hand searching with dates)	p. 8	We carried out a secondary analysis of existing datasets from studies conducted within or in collaboration with the Laval University Primary Care Practice-Based Research Network (PBRN) in the Province of Quebec, Canada. This network comprises twelve family practice teaching units affiliated with Laval University and collaborates with other research networks nationally and internationally. <sup>13</sup>
8	<i>Search</i> (present the full electronic search strategy for at least one database)	N/A	Not applicable.
9	<i>Study selection</i> : State the process for determining which studies were eligible for inclusion (screening)	p. 8	Studies were included if 1) they were set entirely in primary care (defined as the patient's point of entry into the healthcare system, most often consulting a family physician <sup>14</sup> ); 2) they assessed patient-reported decisional conflict using the French or English version of the 16-item Decisional Conflict Scale (DCS) (i.e. studies conducted after the development of the DCS in 1993); <sup>15</sup> and 3) DCS scores were collected from patients following a clinical encounter with a primary care provider. There was no study design restriction.
10	<i>Data collection process</i> (extraction data independently in duplicate and any process for confirming these data with	p. 9	From the baseline data (i.e. before-and-after or randomized controlled trial studies) we extracted the following characteristics of each study: year of data collection, study type,

	investigators)		main objective of original study, clinical setting and types of decision(s) made by patients.
11	<p><i>Data items:</i> describe how the information and variables to be collected were chosen. List and define all study level and participant level, including baseline and follow-up information. If applicable, describe methods of standardizing or translating variables within the datasets to ensure common scales or measurement across studies (list and define all variables for which data were sought)</p>	p. 9	<p>All data collected with patients enrolled in the included studies had been collected using self-administered paper-based questionnaires. The Decisional Conflict Scale (DCS) is a generic 16-item scale developed to provide an instrument to evaluate or adapt decision aids and other decision support interventions to patient needs.<sup>16</sup> When administered in the context of the included studies, a preamble described the specific decision-type addressed, and patients were asked to indicate clearly in their own words the decision they were assessing. Therefore, the DCS items were generic and the same in every case, and participants were thus expected to respond in light of this one specific decision. From the baseline data (i.e. before-and-after or randomized controlled trial studies) we extracted the following characteristics of each study: year of data collection, study type, main objective of original study, clinical setting and types of decision(s) made by patients. For each study, we assessed patient characteristics such as sex, age (&lt;45 years old, ≥45 years old), professional status (full or part-time employment, no employment, retired), education (no postsecondary education, some postsecondary education), annual household income (&lt;CAD \$60,000, ≥\$60,000), household size (living alone, living with at least one other person), marital status (married, single, separated/divorced, widowed), and whether the patient had a private drug insurance plan (yes, no). We also assessed clinical characteristics: whether this was the first encounter with that particular primary care provider (yes, no), whether the patient was accompanied during the encounter (yes, no), whether the decision was for a child (yes, no), patient preference for involvement in decision-making (passive, active<sup>10 17</sup>), average annual frequency of consultations with any doctor (≤3, &gt;3), self-reported health</p>

			status <sup>18</sup> (excellent/very good/good, or fair/poor), whether the patient received a drug prescription (yes, no).
12	<i>Risk of bias in individual studies:</i> Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), report if and how this information is to be used in any data synthesis.	N/A	Not applicable.
13	<i>Summary measures:</i> State all outcomes addressed and define them in detail, and whether they were primary or secondary outcomes. Give the principal measures of effect (e.g., risk ratio, difference in means) used for each outcome.	p. 10	First, we computed CSDC as defined by a score of $\geq 25/100$ on the DCS, <sup>3 4 15 19</sup> at which point decisional conflict is positively associated with decisional delay, departure from active treatment, decision regret, nervousness and a higher intention to sue physicians in cases of harms from treatment. <sup>3 4</sup> This is the threshold most commonly used to distinguish a harmless from a harmful level of decisional conflict. <sup>3 19 20</sup> The DCS consists of 16 items, each of which is measured on a 5-point Likert scale (1 = strongly agree to 5 = strongly disagree, treated as a 0-4 score). The mean score of all items is multiplied by 25 to give a score out of 100. Higher scores indicate higher levels of decisional conflict. <sup>21</sup> The DCS shows good psychometric properties (test-retest reliability coefficient: 0.81, Cronbach's alpha range: 0.78 – 0.92) and its French translation has been validated. <sup>16 22-24</sup>
14	<i>Synthesis of results:</i> Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I <sup>2</sup> ) for each meta-analysis. How effect estimates were generated separately within each study and combined across studies (where applicable). How missing data within studies were dealt.	p. 10	Second, we conducted complete-subject analyses of the prevalence and risk factors of CSDC individually for each dataset at the patient level. After deletion of missing data and removal of participants in experimental groups, patient characteristics were similar to those of the original study populations. <sup>25 26 27 28 29</sup> In studies where clusters of patients were recruited under the same clinician and/or within the same clinic, we assessed the impact of a potential cluster effect at each level of analysis (clinician and/or clinic). For each dataset, we computed overall prevalence of



	Estimation of interactions. Potential effect modifiers.		CSDC and prevalence for each category of available variables stratified by sex. All results pertaining to prevalence are reported as percentages of patients with CSDC. Logistic regression (backwards selection) was used to explore the independent association between CSDC and potential risk factors, including interaction terms with each variable and sex. All significant variables at $\alpha \leq 0.10$ were kept in the final model. We defined statistical significance at $\alpha \leq 0.10$ because this was an exploratory study. If we found a non-negligible cluster effect, we used a generalized estimation equation (PROC GENMOD) with binary logit outcome. Otherwise, logistic regression was used. We calculated the receiver operating characteristic to estimate the models' performance. All analyses were conducted with SAS 9.3 (SAS Institute Inc., Cary, NC, USA).
15	<i>Risk of bias across studies:</i> Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	N/A	Not applicable
16	<i>Additional analyses:</i> Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	p. 10	All methods have been described in point 13 and 14.
<b>RESULTS</b>			
17	<i>Study selection:</i> Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram	pp. 11-12	We included a before-and-after study, two cross-sectional studies, and two randomized studies.
18	<i>Study characteristics:</i> For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	pp12-13	Table 1 presents the characteristics of the included studies and their related datasets alongside the available independent variables. <sup>25-29</sup> All datasets were from projects conducted between 2003 and 2010. Three were conducted in the province of Quebec, one was conducted in Ontario and

			one was conducted jointly by teams from Ontario and Quebec. <sup>28</sup> Of the five datasets available, two were clustered randomized trials (DECISION+25, DECISION+229), two were cross-sectional surveys (GENETIC27, EXACKTE2 28) and one was a before-and-after trial (iODSF26). Decisions were about undergoing a prenatal Down syndrome genetic screening test (GENETIC27), taking antibiotics to treat acute respiratory infections (DECISION+25, DECISION+229) and various other primary care decisions (iODSF26, EXACKTE2 28). Altogether, data from 1,338 primary care patients were analyzed. Patients were aged between 15 and 83 years old and 69% were female.
19	<i>Risk of bias within studies:</i> Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	N/A	Not applicable.
20	<i>Results of individual studies:</i> For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	pp. 16-17	95% confidence intervals are presented with all individual estimates in Table 2: Table 2 shows the prevalence as a percentage of included participants with CSDC across all five datasets stratified by sex for available variables, since gender was found to be a modifying factor for at least one variable in all four datasets that included men. Prevalence was between 10.3% (iODSF26) (95% confidence intervals [CI]: 7.2 – 13.4) and 31.1% (DECISION+229) (95%CI: 26.6 – 35.6). CSDC was consistently more prevalent in males (4/4 studies), people aged 45 or older (4/4 studies), people living alone (4/5 studies), retirees (4/4 studies), people preferring active participation in decision making (2/2 studies), people reporting poor health status (2/2 studies), people making the decision for themselves as opposed to for their children (2/2 studies), and people who did not have a private drug insurance plan (2/2 studies).
21	<i>Synthesis of results:</i> Present results of each meta-analysis done, including confidence intervals and measures of	N/A	Not applicable.

	consistency.		
22	<i>Risk of bias across studies:</i> Present results of any assessment of risk of bias across studies (see Item 15).	N/A	Not applicable.
23	<i>Additional analysis:</i> Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	p. 19	<p>Table 3 present results of association testing with p-values for each dataset:</p> <p>The impact of cluster effect at the clinician level was found to be negligible in all datasets. However, we found a cluster effect at the clinic level in three projects (iODSF26, DECISION+25, DECISION+229). Table 3 presents the multivariable regression analysis of the association between CSDC and its potential independent risk factors. Sex was found to be a modifying factor for at least one variable in all datasets (except GENETIC27, as all participants were women) and an independent risk factor in one (EXACKTE228). We tested the interaction between the patient's gender and the first visit with a physician but found that it was not significant (data not shown). Living alone was positively associated with CSDC in three out of four datasets (iODSF26, DECISION+25, DECISION+229). Being aged 45 or older was also positively associated with CDSC in three out of four datasets (DECISION+25, EXACKTE2 28, DECISION+229) and there was a significant interaction with sex in one dataset (iODSF26). An annual income above or equal to CAD \$60,000 was positively associated with CSDC in two of the five datasets (iODSF26, EXACKTE228) and we observed an interaction term with sex in one dataset (DECISION+25). Other study variables were not significantly associated with CSDC in more than one study.</p>
<b>DISCUSSION</b>			
24	<i>Summary of evidence:</i> Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and	p. 20	Using data on a total of 1,338 patients from combination of five studies conducted in primary care contexts in two Canadian provinces, Quebec and Ontario, we observed that the prevalence of CSDC in patients, defined as a score of $\geq 25/100$ on the DCS,

	policy makers).		<p>was substantial and varied between 10% and 31%. Populations at risk of CSDC included males, people living alone and people aged 45 years or older. ... Given the harmful downstream effects of unresolved CSDC, our results suggest that a significant number of primary care patients would benefit greatly from patient decision aids,[11] decision coaching[35] or from their healthcare providers being trained in shared decision making. These clinical approaches are known to be effective in resolving CSDC.[36] We discussed the more consistent risk factors of CSDC one by one.</p>
25	<p><i>Strengths and Limitations:</i> Discuss strengths and limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).</p>	p. 22	<p>First, measuring CSDC was not the primary objective of any of the selected studies. Also, potentially relevant variables such as marital status and self-reported health status were missing in some datasets, and therefore we could not draw conclusions relating to these variables. Furthermore, all studies were weighted equally, as a meta-analysis was not judged appropriate given the heterogeneity of the data sets (type of decision, study design, available variables). Nevertheless, the similar nature of the questionnaires in each study enabled us to compare associations in datasets independently from one another and thus assure external validity of the results.<sup>47</sup> We also acknowledge that there might be a selection bias in the included studies and thus our results will need to be reproduced in future studies. Also, there might be bias within the studies resulting from patients who willingly participated in the study and regarding the study design. However, we performed multivariate analyses to adjust for confounding factors. Finally, we acknowledge that we cannot infer that our results are generalizable to the wider population as we drew upon secondary analysis of existing datasets of studies conducted in specific primary care clinical contexts in two provinces in Canada. Further studies with appropriate survey methods and sampling frames could depict a more accurate portrait</p>

			of CSDC in other primary care clinical contexts, and explore how much the prevalence varies according to decision-type.
26	<i>Conclusions:</i> Provide a general interpretation of the results in the context of other evidence, and implications for future research.	p. 23	We observed that the prevalence of CSDC in studies on decision-making conducted in primary care contexts in two Canadian provinces, Quebec and Ontario, ranged from 10% to 31%. This prevalence varied depending on the type of decision and was higher in males, in people living alone, and in people aged 45 or older. Although we cannot generalize our results to the wider population, they should alert primary care providers to patients who may be at higher risk of CSDC. Training health professionals to identify CDSC in patients and ensuring that effective decision support interventions such as patient decision aids are implemented at the point of care should be encouraged to resolve CDSC. <sup>12 48</sup>
<b>FUNDING</b>			
27	<i>Funding:</i> Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	p. 2	“FL is Tier-2 Canada Research Chair in Implementation of Shared Decision Making in Primary Care.”